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3PREFACE  
As the World Drug Report 2017 clearly shows, there 
is much work to be done to confront the many 
harms inflicted by drugs, to health, development, 
peace and security, in all regions of the world.
Globally, there are an estimated minimum of 
190,000 — in most cases avoidable — premature 
deaths from drugs, the majority attributable to the 
use of opioids.
The terrible impact of drug use on health can also 
be seen in related cases of HIV, hepatitis and 
tuberculosis. 
Much more needs to be done to ensure affordable 
access to effective scientific evidence-based preven-
tion, treatment and care for the people who 
desperately need them, including those in prison 
settings. As just one example, this year’s report high-
lights the need to accelerate accessibility to the 
treatment of hepatitis C, a disease whose negative 
health impact on people who use drugs is far greater 
than that of HIV/AIDS.   
Recent attention has focused on the threats posed 
by methamphetamine and new psychoactive sub-
stances (NPS). However, as the report shows, the 
manufacture of both cocaine and opioids is increas-
ing. These drugs remain serious concerns, and the 
opioid crisis shows little sign of stopping.
The World Drug Report 2017 further looks at the 
links with other forms of organized crime, illicit 
financial flows, corruption and terrorism. It draws 
on the best available evidence and, most of all, high-
lights the fact that much more research needs to be 
carried out in these areas. 
Corruption is the great enabler of organized crime, 
and opportunities for corruption exist at every stage 
of the drug supply chain. However, too little is 
known about how different types of corruption 
interact with drug markets. 
The outcome document of the special session of the 
General Assembly on the world drug problem and 
I am proud to say that this year we are marking 20 
years of the World Drug Report.
Over the past two decades, the United Nations 
Office on Drugs and Crime (UNODC) has been 
at the forefront of global research into complex areas 
of drug use and supply, supporting international 
cooperation and informing policy choices with the 
latest estimates, information on trends and 
analysis.
This year we are launching a new format, with the 
report available as five separate booklets: the execu-
tive summary, together with the report’s conclusions 
and policy implications; a global overview of drug 
use and supply; a market analysis of plant-based 
drugs; a market analysis of synthetic drugs; and a 
thematic booklet on the links between drugs and 
organized crime, illicit financial flows, corruption 
and terrorism. We have done this in response to 
readers’ needs and to improve user-friendliness, 
while maintaining the rigorous standards expected 
from the Office’s flagship publication. 
The 2017 report comes at a time when the interna-
tional community has acted decisively to achieve 
consensus on a way forward for joint action.
The outcome document unanimously adopted at 
last year’s special session of the General Assembly 
on the world drug problem contains more than 100 
concrete recommendations for implementing bal-
anced, comprehensive and integrated approaches to 
effectively addressing and countering the world drug 
problem. 
Moreover, at its sixtieth session, in March 2017,  the 
Commission on Narcotic Drugs adopted resolution 
60/1, reinforcing commitment to implementing the 
outcome document and charting a course to the 
2019 target date of the 2009 Political Declaration 
and Plan of Action on the world drug problem, as 
well as strengthening action towards the Plan of 
Action’s agreed goals and targets. 
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Security Council resolutions express concern about 
terrorist groups profiting from drug trafficking, 
among other forms of transnational organized crime.
It is well established that there are terrorists and 
non-State armed groups profiting from the drug 
trade — by some estimates, up to 85 per cent of 
opium poppy cultivation in Afghanistan is in terri-
tory under influence of the Taliban. 
However, evidence on the organized crime-terrorism 
nexus remains patchy at best. Moreover, these links 
are not static. Relations between organized crime 
and terrorists groups are always evolving, much like 
drug markets themselves.
As we have seen with the NPS market, drug use, 
supply, trafficking routes and the substances them-
selves continue to shift and diversify at alarming 
speed. 
Drugs continue to represent a major source of rev-
enue for organized crime networks, but business 
models are changing, with criminals exploiting new 
technologies, such as the darknet, that are altering 
the nature of the illicit drug trade and the types of 
players involved, with looser, horizontal networks 
and smaller groups becoming more significant. New 
ways of delivering drugs further point to the need 
to involve other sectors such as postal services in the 
fight against drug trafficking.   
Clearly, countries must be able to act and react to 
an ever-changing and formidable array of threats 
and problems. UNODC is fully engaged in strength-
ening responses, working closely with our United 
Nations partners and in line with the international 
drug control conventions, human rights instruments 
and the 2030 Agenda for Sustainable Development, 
which are themselves complementary and mutually 
reinforcing.
As the special session of the General Assembly and 
the recent session of the Commission on Narcotic 
Drugs have shown, the international community is 
equipped to respond swiftly and decisively to global 
drug-related challenges. 
For example, in March, the Commission scheduled 
two precursors and an analogue to the scheduled 
drug fentanyl. This important step will make it 
harder for criminals to illicitly manufacture fentanyl 
and its analogues and, I hope, can help to stem the 
tragic increase in opioid overdoses in recent years. 
However, there remains an enormous need for 
capacity-building and technical assistance, and fund-
ing continues to fall far short of political 
commitment. Further resources are urgently needed 
to help all Member States implement the recom-
mendations contained in the outcome document 
of the special session of the General Assembly and 
achieve related targets under the Sustainable Devel-
opment Goals.
The many evolving drug challenges also highlight 
the importance of prevention — science- and rights-
based drug use prevention — but also prevention 
of crime, corruption, terrorism and violent extrem-
ism, in line with commitments under the 
conventions and United Nations standards and 
norms. 
Finally, I ask all Governments to help us improve 
the evidence base for these reports. Areas such as 
the links between drugs, terrorism and insurgency 
clearly touch upon sensitive intelligence, and there 
are legitimate concerns about compromising sources, 
collection and operations. But if we want to effec-
tively address drug challenges we need to strengthen 
international cooperation and information-sharing 
to the extent possible, to close the gaps and ensure 
that joint action is targeted, effective and timely. 
Yury Fedotov
Executive Director
United Nations Office on Drugs and Crime
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7EXPLANATORY NOTES 
The boundaries and names shown and the designa-
tions used on maps do not imply official endorsement 
or acceptance by the United Nations. A dotted line 
represents approximately the line of control in 
Jammu and Kashmir agreed upon by India and Paki-
stan. The final status of Jammu and Kashmir has 
not yet been agreed upon by the parties. Disputed 
boundaries (China/India) are represented by cross-
hatch owing to the difficulty of showing sufficient 
detail. 
The designations employed and the presentation of 
the material in the World Drug Report do not imply 
the expression of any opinion whatsoever on the 
part of the Secretariat of the United Nations con-
cerning the legal status of any country, territory, city 
or area, or of its authorities or concerning the delimi-
tation of its frontiers or boundaries.
Countries and areas are referred to by the names 
that were in official use at the time the relevant data 
were collected.
All references to Kosovo in the World Drug Report, 
if any, should be understood to be in compliance 
with Security Council resolution 1244 (1999).
Since there is some scientific and legal ambiguity 
about the distinctions between “drug use”, “drug 
misuse” and “drug abuse”, the neutral terms “drug 
use” and “drug consumption” are used in the World 
Drug Report.
All uses of the word “drug” in the World Drug Report 
refer to substances under the control of the inter-
national drug control conventions.
All analysis contained in the World Drug Report is 
based on the official data submitted by Member 
States to the United Nations Office on Drugs and 
Crime through the annual report questionnaire 
unless indicated otherwise.
The data on population used in the World Drug 
Report are taken from: United Nations, Department 
of Economic and Social Affairs, Population Divi-
sion, World Population Prospects: The 2015 
Revision. 
References to dollars ($) are to United States dollars, 
unless otherwise stated.
References to tons are to metric tons, unless other-
wise stated. R stands for the correlation coefficient, 
used as measure of the strength of a statistical rela-
tionship between two or more variables, ranging 
from 0 to 1 in case of a positive correlation or from 
0 to -1 in case of a negative correlation.  
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Harm caused by drug use remains  
considerable
An estimated quarter of a billion people, or around 
5 per cent of the global adult population, used drugs 
at least once in 2015. Even more worrisome is the 
fact that about 29.5 million of those drug users, or 
0.6 per cent of the global adult population, suffer 
from drug use disorders. 
The magnitude of the harm caused by drug use is 
underlined by the estimated 28 million years of 
“healthy” life (disability-adjusted life years (DALYs)) 
lost worldwide in 2015 as a result of premature death 
and disability caused by drug use. Of those years 
lost, 17 million were attributable solely to drug use 
disorders across all drug types. DALYs attributable 
to morbidity and mortality resulting from all causes 
of drug use have increased overall in the past decade. 
Yet, with fewer than one in six persons with drug 
use disorders provided with treatment each year, the 
availability of and access to science-based services 
for the treatment of drug use disorders and related 
conditions remain limited. 
Opioids, the most harmful drug type 
Opioids, including heroin, remain the most harmful 
drug type in health terms. A significant proportion 
of the large number of premature deaths among 
people who use drugs is attributable to opioids. In 
addition, opioid use disorders account for the 
heaviest burden of disease attributable to drug use 
disorders: in 2015, almost 12 million DALYs, or 70 
per cent of the global burden of disease attributable 
to drug use disorders, were attributable to opioids.
Hepatitis C causing greatest harm among 
people who use drugs 
People who inject drugs (PWID) face some of the 
most severe health consequences associated with 
drug use. Almost 12 million people worldwide inject 
drugs, of whom one in eight (1.6 million) are living 
with HIV and more than half (6.1 million) are living 
with hepatitis C.
The number of deaths attributable to hepatitis C 
among people who use drugs is greater than from 
other causes of death related to drug use. Overall, 
more DALYs are lost as a result of hepatitis C than 
of HIV infection among people who use drugs. Most 
of those DALYs are the result of premature death, 
while the remainder are the result of years lived with 
disability. 
People who use drugs particularly  
vulnerable to tuberculosis
Based on the limited data available from studies in 
Europe, Asia and the Americas, the prevalence of 
tuberculosis among PWID is estimated at approxi-
mately 8 per cent, which compares with less than 
0.2 per cent in the general population. 
People who use drugs may have a particular need 
for interventions that prevent and treat tuberculosis. 
They may be disproportionately affected by the risk 
factors for the disease. Infection with HIV is one of 
the main reasons for the high prevalence of tuber-
culosis among PWID and tuberculosis is one of the 
leading causes of mortality among people who use 
drugs and are living with HIV. 
Treatment of tuberculosis is particularly complex 
for people who use drugs as they may be living with 
multiple, co-existing infectious diseases and psychi-
atric and medical co-morbidities in addition to drug 
dependency. Furthermore, many barriers to the pre-
vention and treatment of tuberculosis are more 
difficult to surmount for people who use drugs than 
for the general population. 
Prison a high-risk environment for the 
spread of infectious diseases
Drug use, including the use of heroin and injecting 
drug use, are commonplace in many prisons. One 
out of three prisoners has used an illicit substance 
at some time while incarcerated, with 16 per cent 
reporting current (past-month) use. Cannabis is by 
far the most commonly used drug in prison, while 
heroin ranks second. Approximately 10 per cent of 
prisoners report using heroin at some time while 
incarcerated, one third of whom report current 
(past-month) use within prison. 
Unsafe injecting practices help to spread HIV among 
PWID in prison populations and ultimately to the 
KEY FINDINGS  
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wider community. People who use drugs who are 
incarcerated are also placed at greater risk of 
tuberculosis.
Higher rate of increase in the burden of 
disease from drug use disorders among 
women than among men
At least twice as many men than women suffer from 
drug use disorders. However, once women have ini-
tiated substance use, in particular, use of alcohol, 
cannabis, opioids and cocaine, they tend to increase 
their rate of consumption more rapidly than men. 
In the past decade, the negative health impact of 
drug use has increased more rapidly among women 
than among men. The rate of increase in the number 
of DALYs attributed to drug use disorders in 2015, 
particularly opioid and cocaine use disorders, was 
greater among women (25 per cent and 40 per cent, 
respectively) than among men (17 per cent and 26 
per cent, respectively). 
Evidence shows that making pharmaceuti-
cal opioids available to the population 
who need them most often does not lead 
to their misuse or addiction 
Despite the fact that pharmaceutical opioids for 
pain management and treatment of opioids use dis-
orders are included in the list of essential medicines 
by WHO, there remain significant gaps and barriers 
in the access to and availability of pain medications 
in most parts of the world. 
Fear of addiction to pharmaceutical opioids 
contributes to the complex dynamics influencing 
access to and availability of controlled medicines. 
However, a structured review of the literature found 
that 3 per cent of chronic non-cancer pain patients 
regularly taking opioids developed opioid use 
disorders.
Opioid market in a constant state of 
change 
The opioid market is becoming more diversified: 
this is illustrated by the example of the United States, 
where the opioid market comprises a combination 
of internationally controlled substances, particularly 
heroin, and prescription medicines that are either 
diverted from the legal market or produced as coun-
terfeit medicines on a large scale. These counterfeit 
medicines are made to look like pharmaceutical 
products while actually containing fentanyl and fen-
tanyl analogues, as well as non-opioid substances 
such as derivatives of benzodiazepine and 
methylphenidate. 
Expansion of the cocaine market
Data on drug production, trafficking and use point 
to an overall expansion of the market for cocaine 
worldwide. Following a long-term decline, coca bush 
cultivation increased by 30 per cent during the 
period 2013-2015, mainly as a result of increased 
cultivation in Colombia. Total global manufacture 
of pure cocaine hydrochloride reached 1,125 tons 
in 2015.
The quantities of cocaine seized are also on the 
increase, reaching a record level of 864 tons in 2015. 
Opium production on the increase 
In 2016, global opium production (6,380 tons) 
increased by one third compared with the previous 
year. Although there was also an increase in the size 
of the area under opium poppy cultivation, the 
major increase in opium production was primarily 
the result of an improvement in opium poppy yields 
in Afghanistan compared with the previous year. 
Global seizures relatively stable
The largest quantities of drugs seized were of can-
nabis, followed by coca/cocaine related substances 
and opioids.  
The sharpest increases in quantities seized over the 
period 2010-2015 were reported for synthetic NPS, 
which increased fourfold, and of ATS, which dou-
bled. Sharp increases, in particular during 2015, 
were also reported for cocaine, in line with reports 
of rising levels of cocaine manufacture. 
Trafficking through the darknet: relatively 
small but growing fast
The darknet allows users to buy drugs with a crypto-
currency, such as bitcoin, and have their purchases 
delivered to them in a concealed manner. Typical 
buyers are recreational users of cannabis, “ecstasy”, 
cocaine, hallucinogens and NPS. They are less likely 
to order heroin or methamphetamine. Although the 
darknet accounts for only a small percentage of drug 
sales, the market has been growing by around 50 
per cent per year in recent years.
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Although presented as a stand-alone publication, 
this booklet constitutes the second chapter of the 
World Drug Report 2017. It provides a global over-
view of the latest estimates of and trends in drug 
use and drug supply, as well as of several cross-cut-
ting issues related to the world drug problem. Such 
issues include the health impact of drug use, includ-
ing trends among people with drug use disorders, 
problem drug use as reflected in treatment demand 
and estimates of the number of people who inject 
drugs (PWID) and of those living with HIV and 
hepatitis. 
The present booklet also examines the global extent 
of drug-related deaths, particularly of fatal overdoses, 
with recent trends in some countries being presented 
as illustrative. A review of tuberculosis among people 
10 million years of life lost as a result of disability caused by drug use
18 million years of life lost as a result of premature death caused by drug use
17 million DALYs attributed to drug use disorders 
DALYs
attributed
to drug use
28 million healthy years of life lost as a result of drug use
17 million healthy years of life lost as a result of drug use disorders
+
years of “healthy”
 life lost as a result 
of disability
=
years of life lost as a 
result of premature 
death
drug use
disability
premature
death
years of 
life lost
birth expected 
life years
DALYs
 28 million 
“healthy” years of life lost
who use drugs, both in the general population and 
in prisons, as well as challenges in the treatment of 
tuberculosis among those groups, is featured for the 
first time in the World Drug Report. An analysis of 
the dynamics of and trends in the misuse of pre-
scription opioids is also included, as is a brief 
discussion of the issues related to making opioid 
painkillers available and accessible to the population 
in need of them. Finally, the booklet contains a 
global overview of the latest estimates of and trends 
in cultivation, production and trafficking of illicit 
drugs, including on the Internet, using the 
darknet.
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2 GLOBAL OVERVIEW OF DRUG DEMAND AND SUPPLY A. Extent of drug use
The number of past-year users of opiates and per-
sons who misuse prescription opioids is estimated 
at about 35.1 million people (range 28.3 million to 
42.7 million), of whom some 17.7 million are esti-
mated to have used opiates (heroin and opium). 
The misuse of pharmaceutical opioids remains of 
concern in many countries, particularly the United 
States of America, where, coupled with an increase 
in heroin and fentanyl use, it has resulted in a 
A. EXTENT OF DRUG USE
A quarter of a billion people use 
drugs globally
It is estimated that a quarter of a billion people, or 
about 5 per cent of the adult population aged 15-64 
years, used drugs at least once in 2015 (range: 158 
million to 351 million),1 meaning that the extent 
of drug use among the world population has 
remained stable over the past five years. Globally, 
over 11 per cent of people who use drugs, or around 
29.5 million people (range: 15.3 million to 43.1 
million), are estimated to suffer from drug use dis-
orders.This means that their drug use is harmfull to 
the point that they may experience drug dependence 
and require treatment. Moreover, the Global Burden 
of Disease Study 2015 estimated that around 17 
million "healthy" years of life lost (disability-
adjusted life years or DALYs)2, 3 were attributable 
to drug use disorders in that year. 
Opioids are the substances that cause the highest 
negative health impact, but cannabis remains the 
world’s most widely used drug, with an annual 
prevalence of 3.8 per cent of the adult population, 
or an estimated 183 million people (range 128 
million to 238 million), having used cannabis in 
the past year. Cannabis use has increased in parts of 
North and South America, while its use is declining 
or stabilizing in parts of Europe, albeit from or at 
high levels. Amphetamines remain the second most 
commonly used drug worldwide, with an estimated 
35 million past-year users (range 13 million to 58 
million), and the use of amphetamines, particularly 
methamphetamine, is perceived to be increasing in 
many subregions, including North America, Oceania 
and most parts of Asia. 
1 These estimates are based on updates by some 25 countries 
in which new data were available, and reflect the best data 
currently available on the global extent of drug use.
2 As defined by the Word Health Organization (WHO), one 
DALY is one lost year of “healthy” life. “Healthy” years of 
life lost is the combination of life lost as a result of prema-
ture death and life lost as a result of disability (any short-
term or long-term health loss).
3 Global Burden of Disease Study 2015 DALYs and HALE 
Collaborators, “Global, regional, and national disability-
adjusted life years (DALYs) for 315 diseases and injuries and 
healthy life expectancy (HALE), 1990-2015: a systematic 
analysis for the Global Burden of Disease Study 2015”,  
The Lancet, vol. 388, No. 10053 (2016), pp. 1603-1658.
Fig. 1 Global trends in estimated number of 
drug users, 2006-2015
Source: UNODC, responses to annual report questionnaire.
Note: Estimates are for adults (aged 15-64) who used drugs in the 
past year.
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Fig. 2 Global trends in the estimated  
prevalence of drug use and prevalence 
of people with drug use problems, 
2006-2015
Source: UNODC, responses to the annual report questionnaire. 
Note: Estimated percentage of adults (aged 15-64) who used 
drugs in the past year. 
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Drugs and infectious diseases that produce the highest negative health 
impact of drug use
The Global Burden of Disease Study 2015 examined the con-
nection between the use of drugsa and the development of 
poor health.b The most negative health consequences of drug 
use are associated with untreated hepatitis C (which can lead 
to liver cirrhosis and cancer) and opioid use disorders. 
The burden of disease is greater for health consequences related 
to hepatitis C than to HIV infection: considerably more deaths 
(222,000 from hepatitis C; 60,000 from HIV) and DALYs (6.3 
million from hepatitis C; 3.0 million from HIV) are attributable 
to hepatitis C than to HIV. Most of those DALYs are the result 
of premature death, while the remainder are the result of years 
lived with disability. 
Opioids remain major drugs in terms of health consequences, 
with nearly 12 million of the total 17 million DALYs attrib-
uted to drug use disorders in 2015 being attributed to opioid 
use disorders.c Opioids also account for the majority of drug-
related deaths in many subregions. The overall burden of disease 
from all causes of drug use increased in the period 2005-2015, 
with DALYs increasing from 24 million to 28 million, whereas 
the burden of disease attributed to drug use disorders alone 
increased from 14 million to 17 million DALYs over the same 
period. The largest increase in DALYs was attributed to opioid 
use disorders, but large increases were also attributed to disor-
ders resulting from use of amphetamines and use of cocaine. 
The fact that opioids, including heroin, account for most of the 
negative health consequences of drug use is also reflected in 
data provided by hospital emergency departments. In Europe, 
opioids and heroin are most frequently associated with acute 
toxicity presentations, with heroin involved in almost one out 
of four cases. Cocaine and cannabis are also prominent (each 
accounting for 16 per cent of presentations), with new NPS, 
mostly synthetic cathinones, and mephedrone in particular, 
accounting for 11 per cent. Polydrug use presentations are also 
common in Europe, being involved in 38 per cent of cases.d
Number of deaths and “healthy” years of life lost (DALYs) attributable to drug use, 2015
Source: “Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic 
risks or clusters of risks, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015”.
Notes: Error bars represent uncertainty intervals. Numbers given in charts are percentage changes from 2005.
a  In the Global Burden of Disease Study, drug use as a risk factor 
is defined as the extent of the population who are dependent on 
opioids, cannabis, cocaine or amphetamines and the population 
who have ever injected drugs (i.e., extent of exposure to drug use 
as a risk factor).
b  Global Burden of Disease Study 2015 Risk Factors Collaborators, 
“Global, regional, and national comparative risk assessment of 
79 behavioural, environmental and occupational, and metabolic 
risks or clusters of risks, 1990-2015: a systematic analysis for the 
Global Burden of Disease Study 2015”, The Lancet, vol. 388 
(2016), pp. 1659-1724.
c  Global Burden of Disease Study 2015 DALYs and HALE Col-
laborators, “Global, regional, and national disability-adjusted 
life years (DALYs) for 315 diseases and injuries and healthy life 
expectancy (HALE), 1990-2015: a systematic analysis for the 
Global Burden of Disease Study 2015”, The Lancet, vol. 388, No. 
10053 (2016), pp. 1603-1658.
d  European Monitoring Centre for Drugs and Drug Addiction, 
Hospital Emergency Presentations and Acute Drug Toxicity in 
Europe: Update from the Euro-DEN Plus Research Group and the 
EMCDDA (Luxembourg, Publications Office of the European 
Union, 2016).
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Problem drug use as reflected in the 
demand for drug treatment
Information on people in treatment for disorders 
related to the use of different drugs can be taken as 
a proxy to understand the nature and extent of prob-
lem drug use. However, this is only a latent indicator 
of trends in the use of drugs, owing to the time lag 
between the period when people start using drugs, 
when they develop drug use disorders and when 
they seek treatment for drug use. 
For people with drug use disorders, the availability 
and access to treatment services, particularly of 
science-based services, remains limited at the global 
level, with one out of six people with drug-use 
disorders being provided with treatment each year. 
On average, among those treated, the proportion 
of people with cannabis and opioid use disorders 
remains larger than the proportion of people with 
disorders related to the use of other substances. It 
is important to understand, however, that there is 
great variability in the definition and practice of 
what constitutes treatment of cannabis use disorders. 
At present, such treatment consists of behavioural 
or psychosocial interventions that may vary from a 
combined and interrelated epidemic and an increase 
in morbidity and mortality related to opioids.4 
There are also indications of a recent increase in 
heroin use in parts of Western and Central Europe, 
suggesting that the long-term downward trend in 
parts of that subregion may be coming to an end. 
With a high prevalence of cocaine use in North 
America (1.8 per cent, Western and Central Europe 
(1.1 per cent) and Oceania (1.5 per cent, primarily 
Australia and New Zealand), it is estimated that 
there are nearly 17 million past-year users of cocaine 
worldwide. Although cocaine use is decreasing or 
stabilizing in parts of Europe, wastewater analysis 
suggests an increase in consumption of the drug in 
the past five years (see booklet 3, chapter B). There 
are also indications of an increase in parts of North 
America. Some 21.6 million people are estimated 
to be past-year users of “ecstasy”, the use of which 
remains high in Oceania (primarily Australia and 
New Zealand), Europe and North America. 
“Ecstasy” use had been declining in Western and 
Central Europe, but since 2013, data from many 
European countries, particularly in Western and 
Central Europe, show an increase in its use.
Many drug users, both occasional and regular, tend 
to be polydrug users. In order to enhance the overall 
psychoactive experience of the drugs taken, they use 
more than one substance concurrently or sequen-
tially to experience a cumulative or synergistic effect, 
making the entire drug-use scenario rather compli-
cated. In many subregions, for example, an 
increasingly complex relationship between the use 
of heroin and synthetic opioids is being observed, 
in which the illicit manufacture of opioids and the 
availability of many “research opioids”, such as 
AH-7921, U-47700, AH-21, MT-45 and many 
analogues of fentanyl, are posing serious public 
health concerns. Moreover, the emergence of syn-
thetic stimulants and new psychoactive substances 
(NPS) and their use in lieu of, or in combination 
with, conventional drugs, are presenting additional 
challenges to health professionals responding to drug 
use-related emergencies and treating people with 
drug use disorders. 
4 Wilson M. Compton, Christopher M. Jones and Grant 
T. Baldwin, “Relationship between nonmedical prescrip-
tion-opioid use and heroin use”, New England Journal of 
Medicine, vol. 374, No. 2 (2016), pp. 154-163.
Fig. 3 Proportion of people in treatment for 
different drugs, global averages
Source: UNODC, responses to annual report questionnaire.
Note: Unweighted average of people in treatment for different 
drugs in different regions. 
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Gender and drug use 
Compared with drug use among men, overall drug use 
remains low among women. At the global level, men 
are three times more likely than women to use can-
nabis, cocaine or amphetamines. By contrast, women 
are more likely than men to misuse prescription drugs, 
particularly prescription opioids and tranquillizers.a, b This 
mainly reflects differences in opportunities to use drugs 
owing to the influence of social or cultural environments, 
rather than intrinsic gender vulnerability.c Women typi-
cally begin using substances later in life than men, but 
once they have initiated substance use, women tend to 
increase their rate of consumption of alcohol, cannabis, 
opioids and cocaine more rapidly than men and may 
progress more quickly than men to the development of 
drug use disorders. 
According to the Global Burden of Disease Study, men 
suffer at least twice as much as women from drug use 
disorders and therefore from the consequences of drug 
use, as expressed in DALYs. Between 2005 and 2015, 
DALYs attributed to drug use disorders increased by 24 
per cent,d which is attributed to an increase in expo-
sure to risk, i.e. an increase in the prevalence of drug 
use disorders, coupled with an increase in the popula-
tion. The relative increase in the prevalence of drug use 
disorders (exposure to risk factors) was higher among 
women than among men in this period.e Similarly, the 
per cent increase in DALYs caused by drug use disor-
ders, particularly opioid and cocaine use disorders, was 
greater among women (25 per cent and 40 per cent, 
respectively) than among men (17 per cent and 26 per 
cent, respectively).
"Healthy" years of life lost (DALYs) attributable to drug use disorders among men and 
women, 2005 and 2015
Source: Global Burden of Disease Data, Institute for Health Metrics and Evaluation.
a  World Drug Report 2015 (United Nations publication, 
Sales No. E.15.XI.6).
b  Christine E. Grella, “From generic to gender-responsive 
treatment: changes in social policies, treatment services, 
and outcomes of women in substance abuse treatment”, 
Journal of Psychoactive Drugs, vol. 40, SARC Suppl. No. 5 
(2008), pp. 327-343.
c  Michelle L. Van Etten and James C. Anthony, “Male-
female differences in transitions from first drug opportu-
nity to first use: searching for subgroup variation by age, 
race, region, and urban status”, Journal of Women Health 
and Gender Based Medicine, vol. 10, No. 8 (2001), pp. 
797-804.
d  Global Burden of Disease Study 2015 DALYs and HALE 
Collaborators, “Global, regional, and national disability-
adjusted life years (DALYs) for 315 diseases and injuries 
and healthy life expectancy (HALE), 1990-2015: a sys-
tematic analysis for the Global Burden of Disease Study 
2015”, The Lancet, vol. 388, No. 10053 (2016), pp. 
1603-1658.
e  Global Burden of Disease Study 2015 Risk Factors Col-
laborators, “Global, regional, and national comparative 
risk assessment of 79 behavioural, environmental and 
occupational, and metabolic risks or clusters of risks, 
1990-2015: a systematic analysis for the Global Burden 
of Disease Study 2015”, The Lancet, vol. 388 (2016), pp. 
1659-1724.
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treatment are still receiving treatment for opioid use 
disorders. Cannabis is the main drug for which drug 
use treatment is sought in Africa, but many coun-
tries, most notably Mozambique, Nigeria, South 
Africa and the United Republic of Tanzania, have 
reported an increasing number of people entering 
treatment for opioid use disorders. 
Information on the number of people in treatment 
for drug use disorders for the first time shows an 
increasing trend in opioid use, including heroin, in 
North and South America, as well as in Eastern and 
South-Eastern Europe, where nearly a third of 
people in treatment for opioid use disorders were 
first-time entrants into treatment. Accounting for 
more than half of those treated, the proportion of 
people seeking treatment for cannabis use disorders 
for the first time remains high at the global level.
Although, overall, nearly one out of three people in 
treatment for the use of tranquillizers and sedatives 
is a woman, women account for only one out of five 
people in treatment for drug use disorders. Younger 
people are seeking treatment for disorders related 
to the use of cannabis and amphetamines (with an 
average age of 24 and 25, respectively) more than 
for other substances, reflecting increasing use of can-
nabis and amphetamines. Meanwhile, people in 
treatment for opioid- or cocaine-related disorders 
are typically in their 30s and, in many subregions, 
reflect an ageing cohort of users in treatment. It 
should be borne in mind, however, that between 40 
one-time online contact, or a brief intervention in 
an outpatient setting, to a more comprehensive 
treatment plan involving the treatment of other 
co-morbidities in an outpatient or inpatient setting.5, 
6, 7, 8
Opioids remain of major concern in South-West 
and Central Asia and in Eastern and South-Eastern 
Europe. In South-Eastern Europe, nearly three out 
of every five people in drug treatment are in treat-
ment for opioid use disorders. Treatment for cocaine 
use remains prominent in North America, Latin 
America and the Caribbean and, to a lesser extent, 
in Western and Central Europe, while ampheta-
mines remain a problem primarily in East and 
South-East Asia and to some extent in North Amer-
ica. The number of people in treatment for disorders 
resulting from use of amphetamines has been 
increasing in Asia, although half of people in 
5 Wayne Hall, Maria Renström and Vladimir Poznyak, eds., 
The Health and Social Effects of Nonmedical Cannabis Use 
(Geneva, WHO, 2016).
6 Jan Copeland, Amie Frewen and Kathryn Elkins, Manage-
ment of Cannabis Use Disorder and Related Issues: A Clini-
cian’s Guide (Sydney, National Cannabis Prevention and 
Information Centre, University of New South Wales, 2009). 
7 Divya Ramesh and Margaret Haney, “Treatment of cannabis 
use disorders”, Textbook of Addiction Treatment: International 
Perspectives, vol. I, Nady El-Guebaly, Giuseppe Carrà and 
Marc Galanter, eds. (Milan, Springer, 2015).
8 Alan J. Budney and others, “Marijuana dependence and its 
treatment”, Addiction Science and Clinical Practice, vol. 4, 
No. 1 (2004), pp. 4-16.
Fig. 4 Primary drug of concern among people in drug treatment, by region, 2015
Source: UNODC, responses to annual report questionnaire. 
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per cent and 80 per cent of people reported in treat-
ment for drug use disorders are diagnosed with 
polydrug use, reflecting the complexity of the drug 
use phenomenon and the challenge of treating 
people with drug use disorders effectively.
Fig. 5 Total number of people in treatment, by drug type and by region, 2015 or latest available 
data 
Source: UNODC, responses to annual report questionnaire.
Note: The figures are based on data for 2015 or the latest year since 2010. The number of people treated for different drugs in a region 
is weighted by the total number of people treated in a country. Member States in Oceania (Australia and New Zealand) do not provide 
information on the proportion of people in treatment for the first time, and therefore information for Oceania is not reflected in the 
above figures. 
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HIV and hepatitis markedly impact on 
people who inject drugs
PWID are a key population at increased risk of HIV 
infection as a result of unsafe injecting practices 
relating to the sharing of contaminated needles and 
syringes. The available data are sparse but suggest 
that, globally, new HIV infections among PWID 
climbed from an estimated 114,000 in 2011 to 
152,000 in 2015.13 The joint UNODC/WHO/
UNAIDS/World Bank estimate for the prevalence 
of HIV among PWID in 2015 is 13.1 per cent. This 
suggests that roughly one in eight people who 
injected drugs in 2015 were living with HIV, which 
equates to 1.55 million PWID infected with HIV 
worldwide. This estimate is based on the reporting 
of HIV prevalence by 118 countries, covering 95 
per cent of estimated PWID. 
By far the highest prevalences of HIV among PWID 
are found in South-West Asia (28.5 per cent) and 
Eastern and South-Eastern Europe (24.0 per cent), 
where rates are approximately twice the global aver-
age (13.1 per cent). Together, China, Pakistan, the 
Russian Federation, Ukraine and the United States 
are home to one in three adults worldwide. How-
ever, the same five countries account for 68 per cent 
of PWID living with HIV. Despite the steady 
decline observed in the numbers of PWID in drug 
dependence treatment institutions (registered drug 
users) in the Russian Federation, the prevalence of 
HIV among registered PWID rose steadily over the 
period 2009-2014, from 13.2 per cent to 19.9 per 
cent.14
Hepatitis C is an infectious disease affecting the 
liver, which is responsible for considerable mortality 
and morbidity among PWID. The burden of disease 
among PWID, including people with a past history 
of injecting drug use (important because the health 
consequences might not be seen for many decades 
after initial infection), is far greater for hepatitis C 
than HIV infection. The number of deaths is more 
than 3.5 times higher for hepatitis C and the number 
of years of “healthy” life lost (as measured by DALYs) 
13 UNAIDS, Get on the Fast-Track: The Life-cycle Approach to 
HIV (Geneva, 2016).
14 Russian Federation, Ministry of Health, Main Indicators of 
Substance Abuse Services in the Russian Federation in 2013-
2014: Statistical Yearbook (Moscow, 2016).
B. HEALTH IMPACT OF  
DRUG USE 
Almost 12 million people worldwide 
injected drugs in 2015
People who inject drugs (PWID) are among the 
most marginalized and disadvantaged drug users. 
They experience poor health outcomes with a greater 
chance of premature death, high rates of potentially 
life-threatening infectious diseases, such as HIV, 
hepatitis and tuberculosis, and increased risk of both 
fatal and non-fatal drug overdoses.9, 10 The situation 
is often made worse by a lack of access to relevant 
evidence-based prevention and treatment services 
for drug dependence and infectious diseases.11, 12 
Infectious diseases acquired through the sharing of 
injection equipment for drug use further impact on 
those who do not inject or use drugs through other 
modes of transmission (for example, sexual).
The joint UNODC/World Health Organization 
(WHO)/Joint United Nations Programme on HIV/
AIDS (UNAIDS)/World Bank estimate for the 
number of people worldwide who injected drugs in 
2015 is 11.8 million (range: 8.6 to 17.4 million), 
corresponding to 0.25 per cent (range: 0.18 to 0.36 
per cent) of the population aged 15-64 years. This 
estimate is based on the reporting of injecting drug 
use from 107 countries, covering 89 per cent of the 
global population aged 15-64 years. 
Subregions where the prevalence of injecting drug 
use is above the global average are Eastern and 
South-Eastern Europe, Central Asia and Transcau-
casia, North America, Oceania and South-West Asia. 
More than half (53 per cent) of PWID worldwide 
reside in just four countries (China, Pakistan, Rus-
sian Federation and United States).
9 Bradley M. Mathers and others, “Mortality among people 
who inject drugs: a systematic review and meta-analysis”, 
Bulletin of the World Health Organization, vol. 91, No. 2 
(2013), pp. 102-123.
10 Louisa Degenhardt and others, “Global burden of disease 
attributable to illicit drug use and dependence: findings 
from the Global Burden of Disease Study 2010”, The 
Lancet, vol. 382, No. 9904 (2013), pp. 1564-1574.
11 Joint United Nations Programme on HIV/AIDS 
(UNAIDS), The GAP Report 2014 (Geneva, 2014).
12 UNAIDS, Do No Harm: Health, Human Rights and People 
Who Inject Drugs (Geneva, 2016).
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is estimated at 7.4 per cent, suggesting that 880,000 
PWID are infected with the disease. 
New, highly effective hepatitis C treatments (direct-
acting antivirals) have been shown to cure 90 to 95 
per cent of chronic hepatitis in 12 or 24 weeks. In 
2015, WHO included direct-acting antivirals in its 
Model List of Essential Medicines18 and, in 2016, 
launched the first global strategy on hepatitis.19 
Despite the high burden of hepatitis C among 
PWID, treatment has occurred at very low levels, 
which is related to the substantial barriers that exist 
for PWID in accessing care.20 These include lack 
of awareness, stigma and discrimination, limited 
access to hepatitis C testing and treatment and the 
cost of the medications. The median cost of a 
18 Model List of Essential Medicines: 19th List (Geneva, April 
2015) (amended November 2015).
19 Global Health Sector Strategy on Viral Hepatitis 2016-2021: 
Towards ending viral hepatitis (Geneva, 2016).
20 Philip Bruggmann and Jason Grebely, “Prevention, treat-
ment and care of hepatitis C virus infection among people 
who inject drugs”, International Journal of Drug Policy, vol. 
26 (2015), pp. S22–S26.
is approximately 2.5 times higher. The vast majority 
of DALYs for both hepatitis C and HIV are the 
result of years of life lost as a result of premature 
death.15 Hepatitis C is highly prevalent among 
PWID, with the joint UNODC/WHO/UNAIDS/
World Bank estimate of 51.5 per cent for 2015, 
suggesting that 6.1 million PWID are infected with 
hepatitis C. For PWID living with HIV, co-infection 
with hepatitis C is highly prevalent, at 82.4 per cent, 
with hepatitis C among those living with HIV 
becoming a major cause of morbidity and mortali-
ty.16 The prevalence of hepatitis B17 among PWID 
15 Louisa Degenhardt and others, “Estimating the burden of 
disease attributable to injecting drug use as a risk factor for 
HIV, hepatitis C, and hepatitis B: findings from the Global 
Burden of Disease Study 2013”, The Lancet Infectious  
Diseases, vol. 16, No. 12 (2016), pp. 1385-1398.
16 Lucy Platt and others, “Prevalence and burden of HCV 
co-infection in people living with HIV: a global systematic 
review and meta-analysis”, Lancet Infectious Diseases, vol. 16, 
No. 7 (2016), pp. 797-808.
17 The hepatitis B prevalence estimate is intended to refer to 
active infection (HBsAg), rather than anti-HBc, which indi-
cates previous exposure. However, it is not always possible 
to differentiate that in the data reported to UNODC. 
Fig. 6 Regional patterns in injecting drug use and HIV among people who inject drugs, 2015 
Source: Responses to the annual report questionnaire; progress reports of UNAIDS on the global AIDS response (various years); 
the former Reference Group to the United Nations on HIV and Injecting Drug Use; published peer-reviewed articles and govern-
ment reports.
Notes: Unlabelled symbols are regional estimates. Subregions are denoted as follows: Europe — Western and Central (WC) and Eastern 
and South-Eastern (ESE); Asia — Central Asia and Transcaucasia (CAT), East and South-East (ESE), South-West (SW), Near and Middle-East 
(NME) and South (S); and the Americas — North America (N) and Latin America and the Caribbean (LAC). For Oceania, estimates are 
based on data from Australia and New Zealand only. 
Part (a): Percentage of population aged 15-64 years who inject drugs. 
Part (b): Number of PWID (outer circle) and number of PWID living with HIV (inner circle). 
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possible consequence of drug use. Ending the global 
epidemic of tuberculosis is part of target 3.3. of the 
Sustainable Development Goals and is the aim of 
the WHO End Tuberculosis Strategy. However, evi-
dence is required to understand how policy on drug 
use can be an inclusive and integral part of the efforts 
to achieve that goal. Tuberculosis is a potentially 
life-threatening infectious disease that is spread from 
person to person by breathing the same air as those 
with active tuberculosis, particularly when they 
cough, sneeze or spit. Despite being preventable and 
curable in most cases, tuberculosis is one of the top 
ten causes of death globally, and more people died 
from tuberculosis in 2015 than from HIV/AIDS. 
Tuberculosis is one of the leading causes of mortal-
ity among people who use drugs and are living with 
HIV.23 One of the high-risk groups for the spread 
of tuberculosis are people who use drugs. Based on 
the limited data available from studies in Europe, 
Asia and the Americas,24 the prevalence of tuber-
culosis among PWID is estimated at approximately 
8 per cent (median prevalence based on 23 studies) 
with a range from 0.2 per cent to 66 per cent. The 
prevalence of tuberculosis in the general population 
at the global level is estimated at less than 0.2 per 
cent.25 
People who use drugs are disproportionately affected 
by risk factors for tuberculosis such as poor social 
circumstances, infection with HIV and periods of 
incarceration. People who use drugs are often socio-
economically disadvantaged and vulnerable to 
poverty, homelessness and malnutrition. Infection 
with HIV is particularly serious because HIV dra-
matically increases the chance of latent tuberculosis 
infection progressing to active tuberculosis.26 Infec-
tion with HIV is a major reason for the high 
prevalence of tuberculosis among PWID.27 Without 
23 WHO, Global Tuberculosis Report 2016 (Geneva, 2016).
24 Pippa Grenfell and others, “Tuberculosis, injecting drug use 
and integrated HIV-TB care: A review of the literature”, 
Drug and Alcohol Dependence, vol. 129, No. 3 (2013), pp. 
180-209, supplemented by responses to annual report ques-
tionnaire.
25 WHO, Global Tuberculosis Report 2015 (Geneva, 2015).
26 Helen McShane, “Co-infection with HIV and TB: double 
trouble”, International Journal of STD and AIDS, vol. 16, 
No. 2 (2005), pp. 95-101.
27 European Centre for Disease Prevention and Control and 
EMCDDA, Prevention and control of infectious diseases 
among people who inject drugs. Joint publications series 
(Stockholm, ECDC, 2011).
12-week course of the medication (sofosbuvir) in 
26 OECD countries was $42,017, ranging from 
$37,729 in Japan to $64,680 in the United States.21
Only a few countries are taking steps towards uni-
versal access to treatment for all people with chronic 
hepatitis C infections. Some examples where action 
has been taken include Australia, which, since March 
2016, has offered universal access to hepatitis C 
treatment and has identified prisoners and PWID 
as priority populations for the expansion of cover-
age of treatment. France has been providing universal 
access to hepatitis C treatment under its national 
health insurance system since September 2016. 
Georgia and Morocco have launched hepatitis C 
elimination programmes, and Portugal announced 
universal access to hepatitis C treatment in 2015.22
Drug use and tuberculosis
In previous World Drug Reports, limited attention 
had been devoted to tuberculosis, despite it being a 
21 Swathi Iyengar and others, “Prices, costs, and affordability of 
new medicines for hepatitis C in 30 countries: an economic 
analysis”, Plos Medicine, vol. 13, No. 5 (2016), pp. 1-22.
22 WHO, Global Report on Access to Hepatitis C Treatment: 
Focus on Overcoming Barriers (Geneva, 2016). 
Fig. 7 Comparison of burden of disease 
from hepatitis C and HIV attributable 
to injecting drug use, including past 
injecting, 2013 
Source: Degenhardt and others, “Estimating the burden of 
disease attributable to injecting drug use as a risk factor for 
HIV, hepatitis C, and hepatitis B.
Notes: DALYs comprise “healthy” years of life lost as a result of 
both premature death and years lived with disability.
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Fig. 8 High-risk factors for aquiring and progressing to active tuberculosis (TB) among people 
who use drugs
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adherence to the full treatment regimen, and 
through person-to-person transmission.32 The 
number of confirmed cases of drug-resistant tuber-
culosis increased globally from 19,500 in 2006 to 
132,500 new cases in 2015.33 Drug use has been 
identified as an independent risk factor for the 
spread of multidrug-resistant tuberculosis in some 
countries.34, 35, 36, 37, 38, 39 The development of 
drug-resistant forms of tuberculosis leaves patients 
with fewer and less effective treatment options. Mul-
tidrug-resistant tuberculosis treatment takes much 
longer and it is more costly to cure, treatment failure 
is much more common and mortality rates are cor-
respondingly higher, particularly among those who 
are living with HIV.40, 41
Drug users in prison contribute to higher 
level of tuberculosis in prison
According to a recently published review,42 people 
who use drugs or have a history of drug use in prison 
32 Surendra K. Sharma and Alladi Mohan, “Multidrug-re-
sistant tuberculosis: a menace that threatens to destabilize 
tuberculosis control”, Chest, vol. 130, No. 1 (2006), pp. 
261-272.
33 Confirmed cases of rifampicin-resistant and multidrug-resis-
tant TB (WHO, Global Health Observatory data repository. 
Available at http://apps.who.int/gho/data/node.home).
34 Pippa Grenfell and others, “Tuberculosis, injecting drug  
use and integrated HIV-TB care: A review of the literature”, 
Drug and Alcohol Dependence, vol. 129, No. 3 (2013),  
pp. 180-209.
35 Laura F. Anderson and others, “Transmission of multidrug-
resistant tuberculosis in the UK: a cross-sectional molecular 
and epidemiological study of clustering and contact trac-
ing”, Lancet Infectious Diseases, vol. 14, No. 5 (2014),  
pp. 406-415.
36 Patrick K. Moonan and others, “Transmission of multi-
drug-resistant tuberculosis in the USA: a cross-sectional 
study”, Lancet Infectious Diseases, vol. 13, No. 9 (2013),  
pp. 777-784.
37 Marta Gomes and others, “Risk Factors for Drug-Resistant 
Tuberculosis”, Journal of Tuberculosis Research, vol. 2, No. 3 
(2014), pp. 111-118.
38 M. Casal and others, “A case-control study for multidrug-re-
sistant tuberculosis: risk factors in four European countries”, 
Microbial Drug Resistance, vol. 11, No. 1 (2005), pp. 62-67.
39 Nino Mdivani and others, “High Prevalence of Multi-
drug-Resistant Tuberculosis in Georgia”, International  
Journal of Infectious Diseases, vol. 12, No. 6 (2008),  
pp. 635-644.
40 Global Tuberculosis Report 2016.
41 Gandhi and others, “Multidrug-resistant and extensively 
drug-resistant tuberculosis”.
42 Dolan and others, “Global burden of HIV, viral hepatitis, 
and tuberculosis in prisoners and detainees”.
treatment, some 5-15 per cent of people with latent 
tuberculosis infection will develop active tubercu-
losis at some point in their lifetime.28 However, 
people living with HIV are 20 to 30 times more 
likely to develop tuberculosis than those without 
HIV.29 Furthermore, periods of incarceration may 
place people who use drugs in a high-risk environ-
ment for the spread of tuberculosis.
Although newly diagnosed cases of tuberculosis are 
declining slightly at the global level, one of the major 
threats and challenges to controlling the disease is 
the development and spread of tuberculosis that is 
resistant to the most effective medications used to 
cure the disease.30, 31 Drug resistance continues to 
emerge and spread as a result of mismanagement of 
tuberculosis treatment, including inadequate com-
pliance with evidence-based treatment and poor 
28 Emilia Vynnycky and Paul E. M. Fine, “Lifetime risks, incu-
bation period, and serial interval of tuberculosis”, American 
Journal of Epidemiology, vol. 152, No. 3 (2000), pp. 247-
263.
29 Candice K. Kwan and Joel D. Ernst, “HIV and Tubercu-
losis: a Deadly Human Syndemic”, Clinical Microbiology 
Reviews, vol. 24, No. 2 (2011), pp. 351-376.
30 Global Tuberculosis Report 2016.
31 Neel R. Gandhi and others, “Multidrug-resistant and exten-
sively drug-resistant tuberculosis: a threat to global control 
of tuberculosis”, The Lancet, vol. 375, No. 9728 (2010), pp. 
1830-1843.
Latent tuberculosis infection
People with latent tuberculosis infection are infected 
with the Mycobacterium tuberculosis bacteria but 
do not have the active disease. They do not feel sick 
or have any symptoms, and they cannot spread the 
disease. Latent tuberculosis infection can be treated 
but, without treatment, it may progress to active 
tuberculosis, particularly among individuals with 
weak immune systems. Latent tuberculosis infec-
tion (which represents a pool of potential cases of 
active tuberculosis) and active tuberculosis are more 
prevalent among people who use drugs than among 
the general population.a, b
a  Robert G. Deiss, Timothy C. Rodwell and Rich-
ard S. Garfein, “Tuberculosis and Illicit Drug Use: 
Review and Update”, Clinical Infectious Diseases, vol. 
48, No. 1 (2009), pp. 72-82. 
b  Pippa Grenfell and others, “Tuberculosis, injecting 
drug use and integrated HIV-TB care: A review of 
the literature”, Drug and Alcohol Dependence, vol. 
129, No. 3 (2013), pp. 180-209.
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Drug use, injecting drug use and HIV in prisons
On any given day there are approximately 10 million people 
held in prison (including for pretrial detention) throughout the 
world,a although the number of people who pass through prison 
each year is considerably higher. Drug use, including the use of 
heroin and injecting drug use, occurs in many prisons, which 
are an environment where the prevalence of HIV is higher than 
among the general population.
Data on the prevalence of HIV among PWID in prison are scarce. 
Based on 34 studies in 16 countries identified in a systematic 
review,b covering the period 2005-2015, the unweighted mean 
prevalence of HIV among PWID in prison was 12.9 per cent. 
However, more than half of the studies were from just three 
countries (Australia, Iran (Islamic Republic of) and United States). 
Of the 34 studies, 4 reported a prevalence of HIV among PWID 
in prison of greater than 40 per cent; 6 studies reported a 
prevalence of greater than 20 per cent; 11 studies reported 
a prevalence of greater than 15 per cent. Overall, 16 studies 
reported a prevalence of greater than 10 per cent, while the 
remaining 18 studies reported a prevalence of below 10 per cent.
Data on the prevalence of HIV in prison populations in general 
are more readily available. People in prisons are five times more 
likely to be living with HIV than adults in the general popula-
tion.c Overrepresentation of PWID among prison populations 
contributes to HIV prevalence in prisons, particularly in countries 
where the HIV epidemic in communities is largely driven by 
injecting drug use.d Globally, an estimated 3.8 per cent (3.2 
per cent to 4.5 per cent) of prisoners are living with HIV.b In all 
subregions, the prevalence of HIV is higher in prisons than in 
the wider community, especially in certain subregions in Africa 
and in Europe and Central Asia (as shown in the figure below), 
where the prevalence of HIV is highest in prison populations 
(8-16 per cent and 4- 5 per cent, respectively). 
People who use drugs often continue to do so while incarcer-
ated, and other prisoners may initiate drug use or injecting 
while in prison. Globally, an estimated one in three prisoners 
have used an illicit substance at some point while incarcerated 
(median lifetime prevalence of 32.6 per cent, based on data 
from 32 studies), with 20.0 per cent reporting use in the past 
year (median past-year prevalence from 45 studies) and 16.0 
per cent reporting current use (median past-month prevalence 
from 17 studies). Heroin is the second most popular drug (after 
cannabis), with 9.6 per cent reporting heroin use at some point 
while incarcerated (median lifetime prevalence from 22 studies) 
and 3.2 per cent reporting current use (median past-month prev-
alence from 18 studies). There is currently limited but increasing 
evidence of the use of NPS (especially synthetic cannabinoids) 
within prisons, but at present it is not possible to quantify the 
extent. Numerous studies have shown that injecting drug use 
is highly prevalent in many prisons, with the sharing of needles 
and syringes commonplace.e Unsafe injecting practices in prison, 
where rates of HIV are high, place PWID at an increased risk 
of HIV through the use of contaminated needles and syringes. 
Prevalence of HIV in prisons compared with the general population, by region, 2005-2015 
Source: Adeeba Kamarulzaman and others, “Prevention of transmission of HIV, hepatitis B virus, hepatitis C virus, and tuberculosis in 
prisoners”, The Lancet, Vol. 388, No. 10049 (2016), pp. 1115-1126.
Note: Error bars represent 95 per cent confidence intervals. Based on a total of 156 studies. Number of studies included in regional estimates of 
HIV in prisons given in square brackets.
a Roy Walmsley, World Prison Population List (eleventh edition), 
Institute for Criminal Policy Research. 
b  Kate Dolan and others, “Global burden of HIV, viral hepatitis, 
and tuberculosis in prisoners and detainees”, The Lancet, vol. 388, 
No. 10049 (2016), pp. 1089-1102.
c  Political Declaration on HIV and AIDS: On the Fast-Track to 
Accelerating the Fight against HIV and to Ending the AIDS  
Epidemic by 2030 (General Assembly resolution 70/266, annex).
d Kate Dolan and others, “People who inject drugs in prison: HIV 
prevalence, transmission and prevention”, International Journal of 
Drug Policy, vol. 26, Suppl No. 1 (2015), pp. S12-S15.
e  Ralf Jürgens, Andrew Ball and Annette Verster, “Interventions to 
reduce HIV transmission related to injecting drug use in prison”, 
Lancet Infectious Diseases, vol. 9, No. 1 (2009), pp. 57-66.
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of PWID are incarcerated at some point in their 
lives.46 Regardless of the offence, the proportion of 
prisoners reporting a history of drug use has been 
estimated at 10-48 per cent for men and 30-60 per 
cent for women.47 The overall higher prevalence of 
tuberculosis observed in prison populations com-
pared with in the general population may be partially 
attributed to the fact that a high proportion of pris-
oners have a history of drug use, and people who 
use drugs might have a history of higher exposure 
to the risk factors for tuberculosis and HIV than 
people in the general population. 
Compared with the general population, people who 
use drugs in prison have a higher risk of contracting 
tuberculosis because of their history of drug use and 
because they are confined in an environment that 
puts them at a higher risk of infection. The risk of 
latent tuberculosis infection and tuberculosis are at 
least one order of magnitude greater in prisons and 
46 The GAP Report 2014.
47 Seena Fazel, Parveen Bains and Helen Doll, “Substance 
abuse and dependence in prisoners: a systematic review”, 
Addiction, vol. 101, No. 2 (2006), pp. 181-191.
contribute to the higher prevalence of infectious 
diseases, including tuberculosis, in prison popula-
tions than in the general population. 
Tuberculosis in prisons is a major public health prob-
lem, particularly in countries where there is a high 
incidence of the disease. The tuberculosis notifica-
tion rate in prisons ranges from 11 to 81 times higher 
than in the general population and the situation is 
worsened by the emergence and spread of drug-
resistant tuberculosis.43 Globally, an estimated 2.8 
per cent (2.05 per cent to 3.65 per cent) of prisoners 
have active tuberculosis, with the highest rates in 
Eastern Europe and Central Asia (4.9 per cent), and 
East and Southern Africa (5.3 per cent).44 The preva-
lence of tuberculosis in European prisons has been 
estimated to be almost 15 times greater than among 
the wider community.45 People with drug use prob-
lems, such as PWID, often spend time in prison: 
according to UNAIDS, an estimated 56-90 per cent 
43 Stefan Enggist and others, eds., Prisons and Health  
(Copenhagen, WHO Regional Office for Europe, 2014).
44 Dolan and others, “Global burden of HIV, viral hepatitis, 
and tuberculosis in prisoners and detainees”.
45 A. Aerts and others, “Tuberculosis and tuberculosis control 
in European prisons”, International Journal of Tuberculosis 
and Lung Disease, vol. 10, No. 11 (2006), pp. 1215-1223.
Fig. 9 Prevalence of tuberculosis in prison populations, by region, 2005-2015
Source: Kate Dolan and others, “Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees”, The Lancet, 
vol. 388, No. 10049 (2016), pp. 1089-1102.
Notes: Diamonds represent regional estimates. Circles are from a single study. The number of studies included in each region is given in 
square brackets. Pooled regional estimates could not be made for the Middle East and North Africa, Western Europe or North America 
because of the lack of studies. For Western Europe, the maximum prevalence from the two studies is presented. No studies from the Car-
ibbean were identified. Error bars represent 95 per cent confidence intervals.
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services in general.50, 51 For those who use drugs 
and who are in treatment for tuberculosis, poor 
adherence and low completion rates have been 
reported.52, 53 These factors increase the likelihood 
that drug resistance will develop, or that tuberculosis 
is not diagnosed and treated, including in those 
infected with the drug-resistant form, with the pos-
sibility of further people being infected. 
Treatment of tuberculosis (especially for drug-resis-
tant forms) is lengthy and complex. It is even more 
complex for people who use drugs as they may be 
living with multiple, concurrent, infectious diseases 
in addition to drug dependency, requiring a partic-
ular effort and an integrated approach to their 
care.54, 55, 56, 57, 58, 59
At least 190,000 mostly preventable 
drug-related deaths in 2015 
Drug-related deaths are the most extreme conse-
quence resulting from drug use. The definition and 
reporting of drug-related deaths may vary from 
country to country but it includes all or some of the 
following conditions: overdoses, deaths from HIV/
50 Robert G. Deiss, Timothy C. Rodwell and Richard S. 
Garfein, “Tuberculosis and Illicit Drug Use: Review and 
Update”, Clinical Infectious Diseases, vol. 48, No. 1 (2009), 
pp. 72-82. 
51 Anya Sarang and others, “Delivery of effective tubercu-
losis treatment to drug dependent HIV-positive patients” 
(Moscow, Andrey Rylkov Foundation for Health and Social 
Justice, 2011).
52 G. M. Craig and others, “The impact of social factors on 
tuberculosis management”, Journal of Advanced Nursing, vol. 
58, No. 5 (2007), pp. 418-424.
53 Deiss, Rodwell and Garfein, “Tuberculosis and Illicit Drug 
Use”. 
54 Ibid. 
55 Grenfell and others, “Tuberculosis, injecting drug use and 
integrated HIV-TB care”.
56 WHO, Integrating Collaborative TB and HIV Services within 
a Comprehensive Package of Care for People who Inject Drugs: 
Consolidated Guidelines (Geneva, 2016).
57 Haileyesus Getahun, Annabel Baddeley and Mario Ravigli-
one, “Managing tuberculosis in people who use and inject 
illicit drugs”, Bulletin of the World Health Organization, vol. 
91, No. 2 (2013), pp. 154-156.
58 WHO, UNODC and UNAIDS, Policy Guidelines for Col-
laborative TB and HIV Services for Injecting and Other Drug 
Users: An Integrated Approach, Evidence for Action Technical 
Papers (Geneva, 2008).
59 Haileyesus Getahun and others, “Tuberculosis and HIV in 
people who inject drugs: evidence for action for tubercu-
losis, HIV, prison and harm reduction services”, Current 
Opinion in HIV AIDS, vol. 7, No. 4 (2012), pp. 345-353.
are estimated to be 26.4 and 23 times higher, 
respectively, than in the corresponding general 
populations.48 Overcrowding, poor ventilation, poor 
nutrition and a lack of screening, prevention and 
treatment of tuberculosis put prisoners at risk of the 
disease. Furthermore, as HIV plays a significant role 
in the spread of tuberculosis, in prison settings where 
there is an absence of evidence-based prevention 
programmes, unsafe injecting practices and the 
associated risk of HIV (see box on page 24) can 
substantially increase the chance of acquiring 
tuberculosis. All those factors can place people who 
use drugs, especially PWID, at increased risk of 
tuberculosis while in prison.
Almost all of the people who are incarcerated will 
eventually return to their communities. The health 
of prisoners will therefore have an impact on the 
general population. Ultimately, the elevated risk of 
tuberculosis in prisons is likely to affect the burden 
of tuberculosis on the general population. In high-
income countries, it has been estimated that 8.5 per 
cent (1 in every 11 cases) of tuberculosis in the gen-
eral population is attributable to exposure in prisons. 
For low- and middle-income countries, the corre-
sponding proportion is 6.3 per cent (1 in every 16 
cases).49 
Challenges in treating tuberculosis among 
people who use drugs
Access to quality treatment and adherence to the 
schedule and completion of treatment are impera-
tive to cure and prevent the development of 
drug-resistant tuberculosis and avoid the further 
spread of the disease to others. Awareness of the 
risks of tuberculosis and the treatment options that 
are available may be low among people who use 
drugs. Certain barriers to care are typically experi-
enced by some people who use drugs, such as the 
fear of reprisal by authorities and the stigmatization 
of drug use. These factors can lead to a delay in 
people seeking treatment, even when they have 
symptoms, and could limit access to or result in the 
underutilization of tuberculosis, HIV and health 
48 Iacopo Baussano and others, “Tuberculosis Incidence in 
Prisons: A Systematic Review”, PLoS Medicine, vol. 7, No. 
12 (2010).
49 Ibid.
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to drug use. In that study, the deaths attributable 
to drug use disorders alone (170,000) match most 
closely those presented by UNODC as being mostly 
related to overdose. In addition, the Global Burden 
of Disease Study 2015 presents deaths related to 
HIV and hepatitis C as well as other causes that are 
mostly omitted from UNODC reporting. 
At more than four times the global average, North 
America continues to experience the highest drug-
related mortality rate, with the subregion accounting 
for more than one in four drug-related deaths glob-
ally. Oceania (based on data from Australia and New 
Zealand only) also has a high drug-related mortality 
rate, at more than 2.5 times the global average. A 
large number of drug-related deaths (35 per cent of 
the global total) are estimated to occur in Asia, 
although this number is tentative because of poor 
regional coverage and reporting of mortality data. 
Despite the large number of deaths, the drug-related 
mortality rate in Asia is below the global average. 
Because of differences in reporting, comparisons 
across countries and regions should be made with 
the greatest of care.
AIDS and hepatitis C acquired through injecting 
drug use; behavioural disorders caused by use of 
psychoactive substances;  intentional self-harm and 
self-poisoning (suicide) by exposure to psychotropic 
substances; and unintentional deaths and trauma 
resulting from drug use (motor vehicle accidents 
and other forms of accidental deaths).
Globally, UNODC estimates that there were 
190,900 (range: 115,900 to 230,100) drug-related 
deaths in 2015, or 39.6 (range: 24.0 to 47.7) deaths 
per million people aged 15-64 years. This is based 
on the reporting of drug-related deaths by 86 coun-
tries. Given differences in the definition and 
reporting of drug-related deaths by Member States 
that often only report on overdose deaths to 
UNODC, and the difficulty in categorically ascer-
taining that a death is in fact drug-related, this global 
estimate is most likely an underestimate of all deaths 
that could be attributable to drug use.60 
The deaths from all causes of morbidity and 
mortality from drug use, as presented by the Global 
Burden of Disease Study 2015, take into account 
most of the causes of  death that could be attributable 
60 World Drug Report 2016 (United Nations publication, Sales 
No. E.16.XI.7).
Fig. 10 Regional variation in drug-related deaths, 2015 
Sources: Responses to the annual report questionnaire; Inter-American Drug Abuse Control Commission; and Louisa Degenhardt and 
others, “Illicit drug use”, in Comparative Quantification of Health Risks: Global and Regional Burden of Disease Attributable to Selected 
Major Risk Factors, vol. 1, Majid Ezzati and others, eds. (Geneva, WHO, 2004).
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The estimated number of drug-related deaths 
remained essentially stable at the global level in 
2015. However, this masks the concern in several 
countries in North America and Europe (where there 
are large numbers of drug-related deaths) that 2015 
was a year in which new record levels of drug-related 
deaths occurred. Opioids were the drug type most 
often implicated in the rising numbers of deaths in 
those countries, and they remain the drug type asso-
ciated with most overdose deaths in many countries, 
although the specific opioid substance may change 
across countries and over time. In the Islamic 
Republic of Iran, for example, opium used to be the 
drug most associated with overdoses, although the 
number of such overdoses has now declined and, 
following recent increases, overdoses involving meth-
adone are now more common (combining 
methadone with other drugs, such as benzodiaz-
epines and/or alcohol, drastically increases the risk 
of fatal overdose).61, 62 
In the United States, where approximately one quar-
ter of estimated global drug-related deaths are 
recorded, overdose deaths continue to rise.63 Mostly 
driven by opioids, overdose deaths more than tripled 
in the period 1999-2015 and increased by 11.4 per 
cent in the past year alone, to reach the highest level 
ever recorded. Recent increases in opioid overdoses 
since 2011 are mostly driven by heroin and synthetic 
opioids other than methadone (a category domi-
nated by fentanyl-related overdoses). Between 2012 
and 2015, overdose deaths from synthetic opioids 
other than methadone increased by 265 per cent, 
and between 2014 and 2015 by 72 per cent (most 
likely driven by illicit fentanyl); in the case of heroin 
overdose deaths, the corresponding increases were 
119 per cent and 23 per cent over those two periods. 
Overdose deaths related to misuse of opioid pain 
relievers other than synthetic opioids (reflecting 
61 United Kingdom, National Treatment Agency for Substance 
Misuse, “Does the combined use of heroin or metha-
done and other substances increase the risk of overdose?” 
(London, February 2007).
62 Hossein Hassanian-Moghaddam and others, “Acute adult 
and adolescent poisoning in Tehran, Iran: the epidemiologic 
trend between 2006 and 2011”, Archives of Iranian Medi-
cine, vol. 17, No. 8 (2014), pp. 534-538.
63 Rose A. Rudd and others, “Increases in Drug and Opi-
oid-Involved Overdose Deaths: United States, 2010-2015”, 
Morbidity and Mortality Weekly Report, vol. 65, Nos. 50 and 
51 (2016), pp. 1445-1452.
Fig. 11 Drug-related deaths from selected 
substances in the United States and in 
England and Wales
Sources: United States, National Institute on Drug Abuse, 
National Center on Health Statistics, Centers for Disease Con-
trol and Prevention Wide-ranging Online Data for Epidemio-
logic Research; and United Kingdom of Great Britain and 
Northern Ireland, Office for National Statistics, “Deaths related 
to drug poisoning in England and Wales: 2015 registrations”, 
Statistical Bulletin (Newport, 9 September 2016).
Notes: For England and Wales, chart shows age-standardized mor-
tality rates per million population, standardized to the 2013 Euro-
pean standard; figures are for deaths registered, rather than 
deaths occurring in each calendar year.
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involving heroin and/or morphine have doubled 
over the past three years to reach their highest levels, 
partly driven by increases in heroin purity and avail-
ability, and also because the ageing cohort of heroin 
users have a range of medical conditions resulting 
from long-term drug use, making them particularly 
vulnerable. Deaths involving cocaine, amphetamine 
(including “ecstasy”) and NPS (most commonly 
mephedrone) also reached an all-time high. Simi-
larly, 706 deaths related to drug misuse were 
registered in Scotland in 2015, which was 15 per 
cent higher than in 2014 and the largest number 
recorded since comparable records began, in 1996.70 
Opioids (including heroin/morphine and metha-
done) were implicated in, or potentially contributed 
to, 606 of those deaths (86 per cent).
C. PHARMACEUTICAL  
OPIOIDS 
Pharmaceutical opioids71 are used effectively in the 
management of acute and chronic pain resulting 
from different conditions and for the treatment of 
opioid use disorders.72, 73, 74 The need for pain 
management can vary from post-surgical care to 
palliative therapy for people with cancer and chronic 
conditions.75 Palliative care is an approach that 
improves the quality of life of patients and their 
families facing problems associated with life-
threatening illness through the prevention and relief 
of suffering by means of early identification, 
assessment and treatment of pain and other related 
problems.76 
70 National Records of Scotland, Drug-related deaths in  
Scotland in 2015 (Edinburgh, 17 August 2016).
71 In this section, the terms “pharmaceutical opioids”, “pre-
scription opioids” and “synthetic opioids” are used inter-
changeably.
72 Charles E. Inturrisi, “Clinical pharmacology of opioids for 
pain”, Clinical Journal of Pain, vol. 18, No. 4 (2002), pp. 
S3-S13.
73 Howard B. Gutstein and Huda Akil, “Opioid analgesics”,  
in Goodman and Gilman’s the Pharmacological Basis of  
Therapeutics, 11th ed., Laurence L. Brunton, ed. (New York, 
McGraw-Hill, 2006), pp. 547-590.
74 WHO, Ensuring Balance in National Policies on Controlled 
Substances: Guidance for Availability and Accessibility of  
Controlled Medicines (Geneva, 2011).
75 Ibid.
76 WHO and World Palliative Care Alliance, Global Atlas of 
Palliative Care at the End of Life, Stephen R. Connor and 
deaths from prescription opioids), although still at 
a high level, have stabilized over the past four years, 
possibly because of changes in policy and changes 
in the health system, including the review of the 
prescription monitoring programme and prescrib-
ing guidelines. Cocaine overdoses have also increased 
recently, largely as a result of the involvement of an 
opioid (mainly fentanyl), with overdoses from this 
drug combination more than doubling since 1999. 
In British Colombia, Canada, the overdose death 
rate (285 per million population aged 15-64 years)64 
is even higher than in the United States (246 per 
million aged 15-64 years), with 914 overdose deaths 
in the province in 2016. That was by far the highest 
number ever recorded, representing an increase of 
79 per cent from 2015 (when there were 510 deaths) 
and a 240 per cent increase from 2012 (when there 
were 269 deaths). Deaths related to the use of fen-
tanyl largely account for the increase observed in 
overdose deaths since 2012.65 
The United Kingdom of Great Britain and North-
ern Ireland accounts for a large proportion (36 per 
cent) of the total number of reported overdose 
deaths that occur in Europe.66 In England and 
Wales, the highest mortality rate from drug misuse67 
since comparable records began in 1993 was 
recorded in 2015, when there were 2,479 deaths, 
an increase of 10.3 per cent from 2014.68, 69 Deaths 
64 Calculation based on the population aged 15-64 in Brit-
ish Columbia in 2016 of 3,209,661 (British Columbia 
Statistics, People, Population and Community, Population 
Estimates). Available at www2.gov.bc.ca/gov/content/data/
statistics/people-population-community/population/popula-
tion-estimates.
65 Canada, British Colombia Coroners’ Service, “Illicit drug 
overdose deaths in BC. January 1, 2007-December 31, 
2016” (Office of the Chief Coroner, Burnaby, British 
Columbia, 18 January 2017).
66 EMCDDA, European Drug Report 2016: Trends and Devel-
opments (Luxembourg, Publications Office of the European 
Union, 2016).
67 The definition of a drug misuse death is either a death 
where the underlying cause is drug abuse or drug depen-
dence or a death where the underlying cause is drug poison-
ing and where any of the substances controlled under the 
United Kingdom Misuse of Drugs Act 1971 are involved.
68 United Kingdom, Office for National Statistics, “Deaths 
related to drug poisoning in England and Wales: 2015 regis-
trations”, Statistical Bulletin (Newport, 9 September 2016).
69 United Kingdom, Office for National Statistics, “Deaths 
related to drug poisoning in England and Wales: 2014 regis-
trations”, Statistical Bulletin (Newport, 3 September 2015).
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cultural attitudes, were also reported as impediments 
to the availability of and access to pain medications.80, 
81, 82 
The fear of addiction to opioid painkillers, despite 
the risk of addiction being very low, contributes to 
the complex dynamics influencing access to and 
availability of controlled medicines. A structured 
review of  67 studies found that 3 per cent of chronic 
non-cancer pain patients regularly taking opioids 
developed opioid use disorders.83 Research has also 
shown that the factors that have been associated 
with increased risk of misuse leading to addiction 
to prescription opioids among patients include 
young age, a history of substance use disorder, major 
depression and the use of other medications, such 
as benzodiazepines.84, 85, 86, 87
Preventing diversion of prescription  
opioids within long-term opioid agonist 
treatment programmes 
Although a valid concern, the diversion of prescrip-
tion opioids, including within long-term opioid 
agonist treatment programmes, can be addressed 
through implementing a set of recommended strate-
gies. In 2015, a systematic review of published 
80 Ensuring Balance in National Policies on Controlled  
Substances.
81 Deborah Dowell, Tamara M. Haegerich and Roger Chou, 
“CDC guideline for prescribing opioids for chronic pain: 
United States, 2016”, Morbidity and Mortality Weekly Report: 
Recommendations and Reports, vol. 65, No. 1 (2016), pp. 
1-49.
82 Nat Wright and others, “Addressing misuse and diversion of 
opioid substitution medication: guidance based on system-
atic evidence review and real-world experience”, Journal of 
Public Health, vol. 38, No. 3 (September 2016), pp. e368-
e374.
83 David A. Fishbain and others, “What percentage of chronic 
non-malignant pain patients exposed to chronic opioid anal-
gesic therapy develop abuse/addiction and/or aberrant drug 
related behaviours? A structured evidence-based review”, 
Pain Medicine, vol. 9, No. 4 (May 2008), pp. 444-459.
84 Dowell, Haegerich and Chou, “CDC guideline for prescrib-
ing opioids for chronic pain”.
85 Jette Højsted and others, “Classification and identification 
of opioid addiction in chronic pain patients”, European Jour-
nal of Pain, vol. 14, No. 10 (2010), pp. 1014-1020.
86 Caleb J. Banta-Green and others, “Opioid use behaviors, 
mental health and pain: development of a typology of 
chronic pain patients”, Drug and Alcohol Dependence, vol. 
104, Nos. 1 and 2 (2009), pp.34-42.
87 Nora D. Volkow and A. Thomas McLellan, “Opioid abuse 
in chronic pain: misconceptions and mitigation strategies”, 
The New England Journal of Medicine, vol. 374, No. 13 
(March 2016), pp. 1253-1263.
Despite the fact that controlled medicines for pain 
relief and for the treatment of opioid use disorders 
are included in the WHO List of Essential 
Medicines, access to them is very limited. It is 
estimated that, each year, millions of people with 
terminal cancer, end-stage AIDS, severe injuries 
caused by accident, women in labour, paediatric 
patients, people recovering from surgery and patients 
with chronic illnesses such as cardiovascular or 
respiratory diseases and diabetes are subjected to 
untreated or undertreated moderate to severe pain.77 
There is strong evidence regarding the efficacy of 
treatment of opioid dependence with long-acting 
opioid agonists (opioid substitution therapy). Such 
treatment can significantly reduce opioid and other 
drug use, criminal activity, HIV risk behaviours and 
transmissions, opioid overdose and all-cause 
mortality, in addition to helping retain people in 
treatment, including antiretroviral therapy and 
tuberculosis treatment.78 
Access to pain medication: key issues 
and considerations
In spite of the need for pharmaceutical opioids for 
the management of different conditions, in most 
parts of the world there remain significant disparities 
in the availability of and access to pain medication 
for improving the quality of life of people suffering 
from those conditions. In 2014, the International 
Narcotics Control Board (INCB) conducted a 
survey on countries’ policies and practices for 
ensuring the availability of narcotic drugs for 
medical and scientific purposes.79 The three major 
areas identified as impediments to the availability 
of and access to pain medications were lack of 
training or awareness among medical professionals, 
fear of addiction and limited resources. Many other 
interlinked factors, such as fear of diversion, fear of 
prosecution, onerous regulatory frameworks or 
sanctions and control measures, and social and 
María C. Sepulveda Bermedo, eds. (London, World  
Palliative Care Alliance, 2014).
77 Ensuring Balance in National Policies on Controlled  
Substances.
78 WHO, Guidelines for the Psychosocially Assisted Pharmacologi-
cal Treatment of Opioid Dependence (Geneva, 2009). 
79 Availability of Internationally Controlled Drugs: Ensuring Ade-
quate Access for Medical and Scientific Purposes−Indispensable, 
Adequately Available and not Unduly Restricted  
(E/INCB/2015/1/Supp.1).
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interventions, including cognitive and behavioural 
approaches and contingency management tech-
niques, along with medically assisted treatment of 
opioid use disorders, were found to be the most 
effective. 
Misuse of prescription opioids
In the past two decades, concerns about the misuse 
of opioids and its related harms have been increas-
ing. Those concerns include dependence and fatal 
and non-fatal overdose resulting from the misuse of 
opioids, particularly in combination with other sub-
stances such as benzodiazepines. High levels of 
misuse of prescription opioids have been seen in 
countries such as Australia and the United States, 
where there is easy access to and some of the high-
est per-capita consumption of opioids for medical 
purposes.89 However, making prescription opioids 
available does not necessarily lead to their misuse 
and addiction. The opposite is also true: some coun-
tries have limits or restrictions on the availability 
and accessibility of opioid painkillers and have low 
per-capita consumption of opioids for medical pur-
poses yet have high levels of misuse of such 
substances.90, 91 
Are the dynamics of the misuse of pre-
scription opioids the same in all regions?
Available literature suggests that the dynamics of 
the misuse of prescription opioids remain different 
in different countries and regions. In North Amer-
ica, the increase in the misuse of prescription opioids 
has been attributed in part to the organization of 
the health system’s structures for regulation and 
access control, prescription practices, dispensing 
and medical culture and patient expectations.92 The 
misuse of prescription opioids in Europe is 
89 E/INCB/2015/1/Supp.1.
90 World Drug Report 2014 (United Nations Publication, sales 
No. E.14.XI.7).
91 Louisa Degenhardt and others, Benefits and Risks of Pharma-
ceutical Opioids: Essential Treatment and Diverted Medication 
– A Global Review of Availability, Extra-Medical Use, Injec-
tion and the Association with HIV (Sydney, National Drug 
and Alcohol Research Centre, University of New South 
Wales, 2007).
92 Bendikt Fischer and others, “Non-medical use of prescrip-
tion opioids and prescription opioid-related harms: why so 
markedly higher in North America compared to the rest of 
the world?”, Addiction, vol. 109, No. 2 (February 2014), pp. 
177-181.
literature identified 37 highly relevant sources of 
evidence on effective strategies to prevent the diver-
sion of prescription opioids in opioid dependence 
treatment programmes.88 Experts were asked to 
review that evidence and, based on their clinical 
experience, rank the list of strategies with high 
impact, which was defined as effectiveness in pre-
venting diversion and ease of implementation. Based 
on the study findings, eight strategies were found to 
have a high impact on preventing the diversion of 
prescription opioids in opioid dependence treatment 
programmes. Those measures included: (a) supervis-
ing consumption among those patients most likely 
to misuse or divert, while providing extended take-
home medications only for patients when their 
dosage and social situation are stable and who accept 
abuse deterrent formulations; and (b) restricting 
take-home formulations that could put children at 
risk through unintentional exposure. Formulations 
that make opioids harder to misuse, particularly in 
the case of opioids that are prone to be injected, can 
be applied in different ways. Such formulations can 
either have a mechanical deterrence, such as being 
crush proof, or contain the addition of an opioid 
antagonist such as naltrexone, to limit misuse and 
diversion. Finally, increasing training for health-care 
practitioners and combining psychosocial 
88 Wright and others, “Addressing misuse and diversion of 
opioid substitution medication”.
Common pharmaceutical  
opioids include:
Morphine, oxycodone, oxymorphone, hydrocodone, 
fentanyl, codeine, buprenorphine, methadone and 
tramadol. 
While morphine is prescribed for the relief of severe 
pain, other opioids such as oxycodone and oxymor-
phone could be prescribed for the management of 
severe to moderate pain.
Fentanyl is used for the management of post-op-
erative pain by intravenous and epidural routes of 
administration. Transdermal patches are used for 
chronic pain, whereas transmucosal dosage is used 
for breakthrough cancer pain.
Opioids such as buprenorphine and methadone are 
also used for the management and treatment of 
opioid use disorders. 
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resulted in a 2.9 per cent increase in the number of 
hospitalizations for heroin overdose.99 Current 
heroin users are also more likely to have used pre-
scription opioids and then switched to heroin 
use.100, 101 Available data suggest that the non-med-
ical use of prescription opioids is neither necessary 
nor sufficient for the initiation of heroin use, and 
other factors could have contributed to the increase 
in heroin use and related mortality.102
In 2015, an estimated 828,000 people aged 12 years 
or older used heroin in the United States and over 
12 million people misused prescription opioids.103 
99 George Unick and others, “The relationship between US 
heroin market dynamics and heroin-related overdose, 1992-
2008”, Addiction, vol. 109, No. 11 (November 2014), pp. 
1889-1898.
100 For details see World Drug Report 2016.
101 Andrew Kolodny and others, “The prescription opioid and 
heroin crisis: a public health approach to an epidemic of 
addiction”, Annual Review of Public Health, vol. 36 (March 
2015), pp. 559-574.
102 Compton and others, “Relationship between nonmedical 
prescription-opioid use and heroin use”.
103 According to the United States Substance Abuse and Mental 
Health Services Administration, misuse of prescription 
drugs is defined as: use in any way not directed by a doctor, 
including use without a prescription of one’s own medica-
considered to have been shaped by the response to 
the opiate problem, in which the misuse of prescrip-
tion opioids, many of which are either diverted from 
legal sources or manufactured illicitly, is seen pri-
marily in the context of legal alternatives to heroin.93 
In middle-income or developing countries, the 
misuse of prescription opioids seems to occur in an 
environment of health-care systems, including the 
systems for the monitoring and dispensing of pre-
scription opioids, that are neither well developed 
nor regulated, coupled with the wider availability 
of counterfeit or illicitly manufactured or trafficked 
prescription opioids to meet the demand for the 
misuse of substances.94, 95
Use of prescription opioids and heroin 
in the United States
The United States is currently experiencing com-
bined and interrelated opioid epidemics of 
prescription opioids and heroin.96 The increase in 
the misuse of prescriptions opioids was driven from 
1997 onwards by the medical practice of prescrib-
ing more and higher doses of opioids,97 which also 
resulted in the diversion and misuse of prescription 
opioids, as they were considered less stigmatized 
than heroin. This was followed in 2010 by changes 
in the formulation of commonly prescribed opioids, 
such as OxyContin,® to make them controlled-
release and tamper proof, thereby preventing their 
misuse by snorting or injecting. From 2007 onwards, 
an increase in heroin use was also observed, which 
was attributed to the availability of pure and cheaper 
heroin in the market.98 It has been shown that each 
$100 decrease in the price per pure gram of heroin 
93 Paul Griffiths, Michael Evans-Brown and Roumen Sedefov, 
“The (mis)use of psychoactive medicines: getting the bal-
ance right in complex system”, Addiction, vol. 109, No. 2 
(February 2014), pp. 182-188.
94 Ibid.
95 Report of the International Narcotics Control Board for 2012 
(E/INCB/2012/1). 
96 Compton and others, “Relationship between nonmedical 
prescription-opioid use and heroin use”.
97 Nicholas B. King and others, “Determinants of increased 
opioid-related mortality in the United States and Canada, 
1990-2013: a systematic review”, American Journal of Public 
Health, vol. 104, No. 8 (August 2014).
98 United States, Center for Behavioral Health Statistics and 
Quality, Key Substance Use and Mental Health Indicators in 
the United States: Results from the 2015 National Survey on 
Drug Use and Health, HHS Publication No. SMA 16-4984, 
NSDUH Series H-51 (Rockville, Maryland, 2016). 
Fig. 12 Misuse of prescription opioids in the 
past year, by age group, United States, 
2015
Source: United States, Center for Behavioral Health Statistics 
and Quality, Key Substance Use and Mental Health Indicators 
in the United States: Results from the 2015 National Survey 
on Drug Use and Health, HHS Publication No. SMA 16-4984, 
NSDUH Series H-51 (Rockville, Maryland, 2016).
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Those figures were similar to those observed in the 
previous few years. Moreover, one third of people 
who had misused prescription opioids in the past 
year (3.8 million) reported using in the past month. 
Among prescription opioids misused in the United 
States, hydrocodone and oxycodone still remain the 
most common, but the use of other opioids such as 
tramadol, morphine and fentanyl is also reported 
not infrequently. The misuse of prescription opioids 
remains highest among those aged 18-25 years, fol-
lowed by among persons aged 26 years and older.
Opioid-related deaths in the United States
The opioid epidemic has taken its toll. Of the 
52,000 total drug-related deaths, those related to 
opioids accounted for more than 60 per cent. Rates 
of deaths involving opioids, specifically heroin and 
synthetic opioids, the latter probably driven primar-
ily by illicit fentanyl, have increased considerably 
across the United States. In 2015, the death rate 
from synthetic opioids, increased by 72 per cent 
compared with the previous year, whereas heroin 
overdose deaths increased by 23 per cent over the 
tion; use in greater amounts, more often, or longer than 
told to take a drug; or use in any other way not directed by 
a doctor.
Fig. 13 Trends in the use of heroin and prescription opioids in the United States, 2002-2015
Source: United States, Center for Behavioral Health Statistics and Quality, Key Substance Use and Mental Health Indicators in the 
United States: Results from the 2015 National Survey on Drug Use and Health, HHS Publication No. SMA 16-4984, NSDUH Series 
H-51 (Rockville, Maryland, 2016).
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Women adversely affected by heroin and prescription opioids in  
the United States
Heroin use in the United States has been increasing since 
2007, with the past-year prevalence of heroin use nearly 
doubling since then. While heroin use has remained high 
among men, the rate of increase of heroin use among women 
has been higher than among men: between 2002 and 2004, 
the average rate of past-year heroin use was 2.4 per 1,000 
men and 0.8 per 1,000 women, whereas between 2013 and 
2015, the rate of past-year heroin use increased to 4.3 per 
1,000 men and 2.0 per 1,000 women.
As discussed above, the increase in heroin use has occurred 
against the backdrop of a prescription opioids epidemic. 
Women, particularly those aged 45 years or older, are more 
likely to suffer from and receive treatment for chronic pain 
related to musculoskeletal conditions or with visceral origins 
(arthritis-related pains, irritable bowel syndrome, fibromyalgia, 
etc.).a, b The most common forms of pain are more prevalent 
among women, and pain is more intense and of longer dura-
tion in women than in men.c, d It is therefore not surprising 
that women use prescription opioids more than men. As the 
progression to addiction to opioids may be accelerated among 
women, the development of addiction among women follow-
ing treatment with opioids for a legitimate medical condition 
(iatrogenic addiction) may explain the comparable levels of 
misuse of prescription opioids among the sexes.e In 2015, 4 
per cent of women, compared with 5.3 per cent of men, had 
misused prescription opioids in the previous year. 
Most heroin users have a history of non-medical use of pre-
scription opioid pain relievers, and an increase in the rate of 
heroin overdose deaths has occurred concurrently with an 
epidemic of prescription opioid overdoses. In 2015, there 
were nearly 13,000 overdose deaths related to heroin use, 
with nearly a quarter of them among women. However, the 
alarming trend is that between 2002 and 2015, heroin over-
dose deaths among women increased nearly ninefold. The 
highest numbers and rates of heroin overdose deaths were 
reported among women aged 25 to 44 years old.f
Trends in heroin use among men and women, 
United States, 2002-2015
Source: Data from Center for Behavioral Health Statistics and 
Quality, Key substance use and mental health indicators in the 
United States 2002-2015. 
Trends in fatal heroin overdoses among men  
and women, United States, 2002-2015
Source: Centres for Disease Control and Prevention  
Wide-ranging ONline Data for Epidemiologic Research.
a  Cynthia I. Campbell and others, “Age and Gender Trends in 
Long-Term Opioid Analgesic Use for Noncancer Pain”, Amer-
ican Journal of Public Health, vol. 100, No. 12 (December 
2010), pp. 2541-2547.
b  Robert W. Hurley and Meredith C. B. Adams, “Sex, gender, 
and pain: an overview of a complex field”, Anesthesia and 
Analgesia, vol. 107, No. 1, pp. 309-317.
c  Robert B. Fillingim and others, “Sex, gender, and pain: a 
review of recent clinical and experimental findings” Journal  
of Pain, vol. 10, No. 5 (May 2009), pp. 447-85.
d  Anita M. Unruh, “Gender variations in clinical pain experi-
ence”, Pain, vol. 65, Nos. 2 and 3 (1996) pp. 123-167.
e  Andrew Kolodny and others, “The prescription opioid and 
heroin crisis: a public health approach to an epidemic of 
addiction”, Annual Review of Public Health, vol. 36 (March 
2015), pp. 559-574.
f  Rose A. Rudd and others, “Increases in Drug and Opioid- 
Involved Overdose Deaths: United States, 2010-2015”,  
Morbidity and Mortality Weekly Report, vol. 65, Nos. 50 and 
51 (2016), pp. 1445-1452.
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years. With approximately 2 mg amounting to a 
lethal dose for humans, fentanyl has a narrow margin 
of safety. Pharmaceutical products containing fen-
tanyl can easily prove toxic if users increase the dose 
or change the route of administration. 
Since 2013, the number of substances containing 
fentanyl reported to and analysed by the National 
Forensic Laboratory Information System in the 
United States has been increasing, and it increased 
dramatically over the period 2014-2015.108 The 
number of reports of fentanyl and other drugs 
within the same item analysed has also increased 
considerably, with 93 per cent of reports showing 
fentanyl and heroin in the same substance. Although 
pharmaceutical fentanyl is diverted for abuse in the 
United States, the majority of reports of fentanyl, 
both individually and mixed with other drugs, result 
from clandestinely produced and trafficked fentanyl, 
rather than from diverted pharmaceutical fenta-
nyl.109 There have also been reports of the emergence 
of many fentanyl analogues, such as acetylfentanyl 
and carfentanyl, and of other synthetic opioids, such 
as AH-7921 and MT-45, in Canada, the United 
States and in Europe. 
108 United States Department of Justice, Drug Enforcement 
Administration, Diversion Control Division, National 
Forensic Laboratory Information System: 2015 Annual Report 
(Springfield, Virginia, 2016).
109 “Special report: opiates and related drugs reported in 
NFLIS, 2009-2014”.
same period.104, 105 It is estimated that nearly 40 
per cent of heroin-related deaths involved fentanyl, 
with many of those who overdose on fentanyl being 
unaware of what they had been using.106 In addi-
tion to being mixed with heroin, fentanyl is also 
sold as other drugs, such as “ecstasy”, or as counter-
feit versions of prescription drugs such as 
OxyContin,® alprazolam and hydrocodone, among 
others. Moreover, the fentanyl analogue acetylfen-
tanyl was also confirmed in at least 25 deaths 
reported by different states during the period 
2013-2014.107 
Appearance of fentanyl and  
its analogues
One of the most potent opioids, fentanyl is increas-
ingly reported in the United States. Mixed with 
other commonly used opioids as well as heroin, it 
has resulted in an upsurge in mortality in recent 
104 Rudd and others, “Increases in drug and opioid-involved 
overdose deaths”.
105 R. Matthew Gladden, Pedro Martínez and Puja Seth, 
“Fentanyl law enforcement submissions and increases in 
synthetic opioid-involved overdose deaths: 27 states, 2013-
2014”, Morbidity and Mortality Weekly Report, vol. 65, No. 
33 (August 2016), pp. 837-843.
106 Richard G. Frank and Harold A. Pollach, “Addressing the 
Fentanyl Threat to Public Health”, New England Journal of 
Medicine, vol. 376, No. 7 (February 2017) pp. 605-607. 
107 United States Drug Enforcement Administration, Office 
of Diversion Control, “Special report: opiates and related 
drugs reported in NFLIS, 2009-2014” (Springfield, Virginia, 
National Forensic Laboratory Information System 2015).
Fig. 15 Number of samples submitted to and analysed by laboratories, by type of drug identified, 
United States, 2009-2015
Source: United States Drug Enforcement Administration, National Forensic Laboratory Information System reports.
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and 2 in the United Kingdom). The presence of 
acetylfentanyl was confirmed in all of those cases.113 
Monitoring of and research into the misuse of pre-
scription opioids in Europe have focused on the 
diversion of buprenorphine and methadone from 
substitution treatment and fentanyl diverted from 
licit channels or illicitly produced.114 However, it 
is important to consider that some potentially 
important developments in the misuse of prescrip-
tion opioids may have remained largely 
underreported in Europe because of the limitations 
of current monitoring systems. For example, the 
misuse of tramadol, gabapentin and pregabalin (both 
used to treat epilepsy) appears to be increasing, 
although it is difficult to detect using the routine, 
available data sources.
European Union Medicine Study
Implemented as a parallel series of national surveys 
conducted in Denmark, Germany, Spain, Sweden 
and the United Kingdom in 2014,115 the European 
Union Medicine Study looked at the extent of the 
non-medical use of prescription drugs (stimulants, 
opioids and sedatives) and its characteristics among 
persons aged 12 to 49 years. The past-year preva-
lence of the non-medical use of opioids among 
respondents was estimated at 5 per cent, with the 
highest prevalence of both lifetime and past-year 
use among those living in Spain, followed by the 
United Kingdom. Comparable levels of misuse of 
prescription opioids were seen among men (past-
year prevalence of 5.7 per cent) and among women 
(past-year prevalence of 4.2 per cent). 
Higher levels of misuse of prescription opioids were 
seen among older age groups and the unemployed. 
Being arrested in childhood (prior to age 15) and 
having a sexually transmitted disease or HIV were 
also associated with a greater likelihood of past-year 
misuse of prescription medications, including 
113 EMCDDA and Europol, Acetylfentanyl: EMCDDA–Europol 
Joint Report On A New Psychoactive Substance: N-phenyl-N-
[1-(2-phenylethyl)piperidin-4-yl]acetamide (acetylfentanyl), 
Joint Reports Series (Luxembourg, Publications Office of 
the European Union, 2016).
114 Griffiths, Evans-Brown and Sedefov, “The (mis)use of psy-
choactive medicines”.
115 Scott P. Novak and others, “Nonmedical use of prescription 
drugs in the European Union”, BMC Psychiatry, vol. 16 
(2016).
Misuse of opioids in Europe
The misuse of prescription opioids in Europe has 
been primarily observed in the context of heroin 
use. In the past decade, the availability of heroin has 
declined in Europe,110 while the availability of sub-
stitution treatment for heroin use disorders has 
increased considerably. Thus, transitions between 
heroin and other opioids, such as fentanyl and 
opioid substitution medicines, have been observed 
in parts of Europe. In some countries, such as Esto-
nia and Finland, where the heroin market 
plummeted in 2002 and 2001, respectively, heroin 
has been entirely displaced by fentanyl (mostly 
illicit) and buprenorphine, respectively. In recent 
years, prescription opioids and new synthetic opi-
oids, which can be purchased online, have also been 
appearing in other markets in Europe.111 
While heroin still remains the most commonly used 
opioid in Europe, and the opioid for the use of 
which most people seek treatment, there has been 
an increase in treatment demand related to prescrip-
tion opioids. In 2014, 18 countries reported that 
more than 10 per cent of all opioid treatment admis-
sions were for problems related to opioids other than 
heroin, an increase from 11 countries in 2013. The 
most common opioids for the use of which treat-
ment was sought were methadone (diverted), 
buprenorphine, fentanyl, codeine, morphine, trama-
dol and oxycodone. Similarly, opioids other than 
heroin seized in European countries in 2014, 
although not in large quantities, were opium, mor-
phine, methadone, buprenorphine, tramadol and 
fentanyl. Some pharmaceutical opioids seized may 
have been diverted from pharmaceutical supplies, 
while others were manufactured specifically for the 
illicit market.112 The availability of acetylfentanyl 
has also been reported in the European Union since 
at least 2013 and has been detected in nine coun-
tries. Although the quantities of acetylfentanyl seized 
are small, it still remains a concern, especially given 
the 32 reported deaths in Europe between 2013 and 
2015 (2 in Germany, 1 in Poland, 27 in Sweden 
110 European Drug Report 2016: Trends and Developments.
111 EMCDDA and European Police Office (Europol), EU Drug 
Markets Report: In-Depth Analysis, Joint publications series 
(Luxembourg, Publications Office of the European Union, 
2016).
112 European Drug Report 2016: Trends and Developments.
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opioids. However, the prescription of a pain reliever 
was associated with a risk of non-medical use of 
prescription opioids some eight times higher than 
other predictors. 
Consistent with findings in the United States, most 
people reporting past-year misuse of prescription 
opioids in the five European countries in the study 
had obtained them through their social networks 
(i.e., from friends or family), but many had also 
stolen or obtained them fraudulently from a doctor. 
Also consistent with findings in other recent reports, 
the European Union Medicine Study showed that 
the purchase of prescription opioids from online 
pharmacies also figured as one of the sources. 
Among other findings, polydrug use, particularly 
the use of illicit drugs among past-year non-medical 
prescription opioid users, was also quite common 
in the five European countries, ranging from 21 per 
cent of past-year users in Spain to 43 per cent in the 
United Kingdom. Among people reporting the non-
medical use of prescription opioids, those more likely 
to engage in use of illicit drugs were also more likely 
to report severe psychological distress and to have 
Fig. 17 Misuse of prescription opioids, by sex, 
age and employment status, five  
European countries
Source: Scott P. Novak and others, “Nonmedical use of  
prescription drugs in the European Union”, BMC Psychiatry, 
vol. 16 (2016).
Fig. 16 Misuse of prescription opioids among 
12-49 year olds, five European countries
Source: Scott P. Novak and others, “Nonmedical use of  
prescription drugs in the European Union”, BMC Psychiatry, vol. 
16 (2016).
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Fig. 18 Sources of non-medical prescription 
drugs among past-year users, five  
European countries
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been arrested during childhood. Similarly, those who 
obtained prescription opioids through theft, forgery 
or doctor-shopping were about twice as likely to 
have used illicit drugs as those who had not.
Although at lower levels than in the United States, 
the misuse of prescription opioids and the appear-
ance of new synthetic opioids that can be purchased 
online are appearing in Europe and are likely to have 
increasing importance for both public health and 
law enforcement in the coming years. 
Misuse of tramadol in Africa and Asia
Tramadol is an opioid that is widely used to treat 
moderate to severe pain, and has also been used in 
the treatment of sexual dysfunction, such as prema-
ture ejaculation.116 In addition to the high levels of 
misuse of prescription opioids reported by many 
countries in Asia and Africa,117 there is growing 
evidence of the non-medical use of tramadol in some 
countries in Africa and the Near and Middle East. 
These have been corroborated in recent years by 
seizures of considerable amounts of tramadol in 
North, West and Central Africa and in the Near and 
Middle East.118 Between 2012 and 2014, the 
Islamic Republic of Iran, countries in the Near and 
Middle East and many countries in Africa reported 
to UNODC that seizures had been made of large 
amounts of tramadol that was being trafficked into 
those countries. Countries in the Middle East 
reported seizures of 310 kg in 2012; a quantity that 
increased to over 22 tons in 2014. Similarly, in 
Benin, the Central African Republic, Cote d’Ivoire, 
Niger and the Sudan, over 300 kg of tramadol were 
seized in 2013 and over 2.6 tons in 2014. In 2015, 
Benin alone reported a seizure of 110 tons of the 
substance. The non-medical use of tramadol has 
been reported by many countries, including Egypt, 
Jordan, Lebanon, Libya, Mauritius, Saudi Arabia 
and Togo, and many have put tramadol under 
national control in recent years. 
Misuse of tramadol among adolescents and young 
people in countries such as Egypt, Iran (Islamic 
116 Emad A. Salem and others, “Tramadol HCl has promise in 
on-demand use to treat premature ejaculation”, Journal of 
Sexual Medicine, vol. 5, No. 1 2008, pp.188-193.
117 See World Drug Report 2014 and World Drug Report 2015. 
118 E/INCB/2012/1.
Republic of ) and the United Arab Emirates has been 
reported as quite common. For example, in a study 
of people with drug use disorders in an outpatient 
addiction clinic in Egypt during the period 2012-
2013, tramadol was the most common opioid 
used,119 the majority of whom were polydrug users. 
In a study of secondary school students in Egypt in 
2013, the most commonly used substances were 
tramadol, cannabis and alcohol. In a study among 
adolescents in the Islamic Republic of Iran in 2013, 
the lifetime prevalence of tramadol use was 4.8 per 
cent (7.6 per cent among males and 1.8 percent 
among females). Polydrug use was common with 
the likelihood of past-month use of other substances 
such as alcohol, “ecstasy”, methamphetamine and 
opium was reported as high among that cohort of 
adolescents.120 
In the United Arab Emirates, a cohort study in 2015 
of male patients at the national treatment centre 
showed opioids and alcohol to be the most common 
substances used.121 Nearly 67 per cent of opioid 
users were using tramadol for non-medical purposes. 
Among the older group within the cohort (those 
aged 30 years or older), heroin was the most com-
monly used opioid; tramadol and codeine were 
commonly used and preferred over heroin among 
the younger group. The majority of the cohort using 
tramadol were doing so on a daily basis, at an aver-
age of eight to nine tablets (100 mg per tablet). The 
proportion of polydrug users in the cohort was also 
high, with nearly 85 per cent being polydrug users, 
of whom the majority had been using a combina-
tion of four or more substances. 
Common reasons cited for the misuse of tramadol 
in the above-mentioned studies included its mood-
enhancing effect, to prolong sexual intercourse, to 
119 Nabil R. Mohamed and others, “An epidemiological study 
of tramadol HCl dependence in an outpatient addiction 
clinic at Heliopolis Psychiatric Hospital”, Menoufia Medical 
Journal, vol. 28, No. 2 (2015), pp. 591-596.
120 Milad Nazarzadeh, Zeinab Bidel and Kristin V. Carson, 
“The association between tramadol hydrochloride misuse 
and other substances use in an adolescent population: phase 
I of a prospective survey”, Addiction Behaviors, vol. 39, No. 
1 (2014), pp. 334-337.
121 Hiba Alblooshi and others, “The pattern of substance use 
disorder in the United Arab Emirates in 2015: results of 
a National Rehabilitation Centre cohort study”, Journal 
of Substance Abuse Treatment, Prevention and Policy, vol. 
(2016).
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Fig. 19 Number of countries reporting drug 
cultivation,a 2010-2015
a Countries reporting cultivation, production and eradication of 
cannabis plants, opium poppy and coca bush, countries reporting 
seizures of cannabis plants, opium poppy plants and coca bush, 
and countries identified by other Member States as countries of 
origin for cannabis plants, opium poppy plants and coca leaf. 
Source: UNODC, responses to the annual report questionnaire. 
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Cultivation of opium poppy remains at high 
levels and the downward trend in coca bush 
cultivation has come to an end 
At 305,000 hectares, the total global area under 
opium poppy cultivation in 2016 was roughly twice 
the size of the total area under coca bush cultivation. 
Representing an increase in size of 60 per cent over 
the period 2010-2016, largely as a result of the rise 
in opium poppy cultivation in Afghanistan, this is 
the second-largest total area under opium poppy 
cultivation recorded in recent years (after the peak 
in 2014). However, as opium poppy surveys were 
not conducted in Myanmar (the world’s second larg-
est opium-producing country in 2015) or in the 
Lao People’s Democratic Republic in 2016, the 
global estimates for 2016 have to be interpreted with 
caution.128
Mostly linked to a decrease in coca bush cultivation 
in Colombia, the global area under coca bush 
128 Myanmar and the Lao People’s Democratic Republic 
together accounted for 22 per cent of the total global area 
under opium poppy cultivation and 12 per cent of total 
opium production over the period 2010-2015. The 2015 
estimates have been used here as proxies for opium poppy 
cultivation and production in both countries for 2016.
relieve fatigue and as self-medication for pain relief 
or depression or anxiety. The non-medical use of 
prescription opioids in the Near and Middle East 
and North Africa, particularly among young people, 
appears to be more for recreational purposes than as 
a result of developing addiction (iatrogenic addic-
tion) following treatment for a legitimate medical 
condition involving pharmaceutical opioids.122 Dif-
ferent studies have concluded that the high levels of 
misuse of tramadol are a result of its easy availability 
in pharmacies and on the illicit market (as it is traf-
ficked in large quantities), its lower price compared 
with illicit drugs, perceptions among users that tram-
adol is safe as it is a prescription medication, and the 
ease with which it can be hidden.123, 124, 125, 126
D. EXTENT OF DRUG SUPPLY
Cultivation and production
On the basis of reports received by Member States, 
there are strong indications that cannabis continues 
to be the most widely illicitly produced drug world-
wide, both in terms of the size and geographical 
spread of the area under cultivation and the volume 
actually produced. Over the period 2010-2015, cul-
tivation of cannabis was reported to UNODC, 
directly or indirectly, by 135 countries in all regions, 
covering 92 per cent of the total global popula-
tion.127 This is almost triple the 49 countries (mostly 
in Asia) where opium poppy cultivation might take 
place and more than 16 times the number of coun-
tries (8, all located in the Americas) where coca bush 
cultivation might take place.
122 David F. Musto, “Iatrogenic addiction: the problem its 
definition and history”, Bulletin of the New York Academy of 
Medicine, vol. 61, No. 8 (October 1985), pp. 694-705. 
123 Nazarzadeh, Bidel and Carson, “The association between 
tramadol hydrochloride misuse and other substances use in 
an adolescent population”.
124 Alblooshi and others, “The pattern of substance use disorder 
in the United Arab Emirates in 2015”.
125 Mohamed and others, “An epidemiological study of trama-
dol HCl dependence in an outpatient addiction clinic at 
Heliopolis Psychiatric Hospital”.
126 This is especially true in countries where possession of alco-
hol and illicit drugs carries severe penalties.
127 Some 80 per cent of all countries from which UNODC 
received data through the annual report questionnaire.
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2013-2015. Based on the “new” conversion ratios, 
total cocaine production in 2015 was 1,125 tons, 
representing an overall increase of 25 per cent over 
the period 2013-2015, and thus a return to its 2008 
level.129 
After cannabis, cocaine accounts for 
the largest quantities seized 
The distribution of seizures across the different drug 
types can be analysed in terms of number of cases 
and quantity seized. These two types of analysis 
show slightly different patterns. 
The distribution of drug seizure cases reported 
worldwide in 2015 shows that more than half of 
seizure cases were of cannabis (mostly cannabis 
herb), followed by ATS (mostly methamphetamine), 
opioids (mostly heroin), coca/cocaine-related sub-
stances and NPS (mostly synthetic cannabinoids, 
followed by plant-based NPS (mostly khat), syn-
thetic cathinones and ketamine).
After cannabis (primarily cannabis herb and, to a 
lesser extent, cannabis resin), the largest seizures at 
the global level in 2015, in terms of quantity, 
involved coca/cocaine-related substances. Excluding 
seizures of coca leaf, the bulk of all coca-related sei-
zures were in the form of the end product, cocaine 
129 More information on the “old” and “new” conversion ratio 
can be found in the online methodology section of the 
World Drug Report 2017.
cultivation was nearly halved during the period 
2000-2013. The global area then increased by 30 
per cent during the period 2013-2015, mainly 
because coca bush cultivation started to increase 
again in Colombia, which has offset the decreasing 
levels of coca bush cultivation reported by Bolivia 
(Plurinational State of ) and Peru in recent years. 
Reaching 156,500 hectares in 2015, the global area 
under coca bush cultivation was more or less the 
same as in 2010, but still 29 per cent less than its 
peak in 2000.
Recent increase in opium production 
In 2016, global opium production showed an 
increase of some 30 per cent compared with the 
previous year. Greater than the increase in the size 
of the area under cultivation, this was primarily the 
result of improved yields in Afghanistan, where there 
was a partial recovery from the very low levels 
recorded in the previous year. However, at 6,380 
tons, total global opium production was still some 
20 per cent lower than the peak in 2014, and close 
to the average reported in recent years. 
Cocaine manufacture is on the increase 
again 
Irrespective of the conversion ratios used for con-
verting coca leaf to pure cocaine hydrochloride, total 
cocaine manufacture fell during the period 2006-
2013, before increasing again during the period 
Fig. 20 Total area under opium poppy and coca bush cultivation, 1998-2016 
Sources: UNODC coca and opium surveys in various countries; responses to the annual report questionnaire; and United States, 
Department of State, International Narcotics Control Strategy Report, various years.
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equivalents, the largest quantities of opioids seized 
were of pharmaceutical opioids (mostly tramadol 
in 2015, followed by codeine and hydrocodone) 
and heroin. The next-largest quantities reported 
were of NPS, the largest seizures of plant-based NPS 
being of khat, followed by kratom. The largest sei-
zures of synthetic NPS reported were of ketamine, 
followed by synthetic cannabinoids and synthetic 
cathinones. The largest quantities of ATS seized were 
of methamphetamine, followed by amphetamine 
and “ecstasy”. 
hydrochloride, which accounted for almost 90 per 
cent of all cocaine seizures, while “crack” cocaine 
seizures accounted for less than 1 per cent of cocaine 
seizures.
The largest quantities of opioids seized involved 
opium. Although expressed in morphine or heroin 
Fig. 21 Global potential opium production 
and global (100 per cent pure) cocaine 
manufacture, 1998-2016
Sources: UNODC coca and opium surveys in various countries; 
responses to the annual report questionnaire; and United 
States, Department of State, International Narcotics Control 
Strategy Report, various years.
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Source: UNODC, responses to the annual report questionnaire.
Note: Based on information from 64 countries. 
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pharmaceutical opioids increased sharply over the 
period 2010-2015, driven by sharp increases in the 
quantities of tramadol, hydrocodone and fentanyl 
seized. Notwithstanding some increases in seizures 
of cannabis resin, the amount of cannabis seized 
declined slightly over the period 2010-2015 as 
whole, although they showed an upward trend from 
2012. 
Drug trafficking over the darknet  
continues to increase at a fast pace 
The “surface web”, which is accessible through tra-
ditional search engines, contains just 4 per cent of 
all information available on the Internet. The 
remaining 96 per cent is stored on the “deep web”. 
A part of it, the darknet, contains information that 
is intentionally hidden and only accessible using 
special web browsers.130 The darknet is used for all 
kinds of activities, illicit included, particularly drug 
trafficking. Users typically access the darknet 
through the “Onion router” (TOR) to ensure that 
130 EU Drug Markets Report.
Increases in seizures reported mainly for 
synthetic drugs and cocaine 
As a result of sharp increases in the quantities of 
amphetamine and methamphetamine seized, total 
seizures of ATS doubled over the period 2010-2015. 
Seizures of “ecstasy” were on the decline until 2011, 
but probably started to increase thereafter, reflecting 
increased supply due to improved access to alterna-
tive precursor chemicals and/or pre-precursors used 
in the drug’s manufacture. 
The quantities of synthetic NPS seized increased 
fourfold over the period 2010-2015, reflecting a 
sharp increase in seizures of synthetic cannabinoids 
and synthetic cathinones, although seizures of syn-
thetic cannabinoids have actually fallen in recent 
years. Overall, plant-based NPS seizures declined 
after 2010, owing to a decrease in the amount of 
khat seized. 
Seizures of cocaine increased over the period 2010-
2015, in particular during 2015, in line with reports 
of rising levels of cocaine manufacture. Although 
seizures of opiates remained stable, seizures of 
Fig. 23 Global drug seizures of selected drugs, by quantity, 2010-2015
Source: UNODC, responses to the annual report questionnaire.
Note: A rate of 10:1 was used to convert seizures of opium into seizures expressed in heroin equivalents.
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Studies show that while the proportion of drug 
market operations through the Internet remains 
small, their rapid growth may represent a significant 
threat.135 Information on the extent to which drug 
users purchase drugs over the Internet can be found 
in the findings of the Global Drug Survey, which 
has been conducted several times in recent years. 
Although these data are derived from a non-repre-
sentative sample, the self-reports of around 100,000 
Internet users in over 50 countries provide a rough 
idea of the propensity of drug users to obtain drugs 
over the darknet, as well as how easily they can access 
it. Among survey participants who had used drugs 
in the past year, the proportion who obtained drugs 
over the darknet in the previous 12 months rose by 
70 per cent during the period 2014-2017.
An increase in use of the darknet was particularly 
pronounced in the United Kingdom, where the pro-
portion of annual drug users participating in the 
survey who reported having obtained drugs over the 
darknet has doubled since 2014 to reach 25.3 per 
cent in 2017, and in the United States, where the 
proportion increased more rapidly but then declined 
slightly in 2017 to 13.2 per cent.136
Nonetheless, this suggests that the upward trend in 
the use of the darknet continues to gain momentum 
in some countries, despite various market disrup-
tions, linked to the closure of several darknet market 
sites by the authorities, as well as exit scams in which 
market owners closed down their sites unexpectedly, 
stealing funds from their clients.
The increases in the use of the darknet for drug 
purchases are remarkable as, overall, drug traffick-
ing (not limited to the darknet) appears to have 
increased only slightly in recent years: from 2.1 mil-
lion cases in 2013 to 2.4 million cases in 2015.137 
joint investigations to combat drug trafficking via the vir-
tual market (darknet) in the European Union, held in Bad 
Erlach, Austria, from 10 to 12 November 2015.
135 Kristy Kruithof and others, Internet-facilitated Drugs Trade: 
An Analysis of the Size, Scope and the Role of the Netherlands, 
Research Report Series (Santa Monica, California, Rand 
Corporation, 2016).
136 Global Drug Survey 2017, detailed findings on drug crypto-
markets. Available from Dr. Monica Barratt, National Drug 
and Alcohol Research Centre, Australia.
137 This is based on overall seizure case data reported to 
UNODC through the annual report questionnaire, which 
increased only slightly in recent years.
their true identities remain concealed.131 According 
to the European Police Office (Europol), as of Janu-
ary 2017, the TOR network had over 1.7 million 
directly connecting users and hosted over 60,000 
unique domains.132 Products bought on market-
places on the darknet are typically paid for in 
crypto-currencies, such as bitcoins, which can be 
subsequently used to purchase other goods and ser-
vices or can be exchanged into various national 
currencies. Delivery of the drugs is usually carried 
out by public or private postal services,133 
and parcels are often sent to anonymous post office 
boxes or automated booths (“pack stations”) 
designed for self-service parcel collection.134 
131 EMCDDA, The Internet and Drug Markets, Insights Series 
No. 21 (Luxembourg, Publications Office of the European 
Union, 2016).
132 Europol, SOCTA 2017: European Union Serious and Organ-
ised Crime Threat Assessment – Crime in the Age of Technology 
(The Hague, 2017), p. 22.
133 World Customs Organization, Illicit Trade Report 2015 
(Brussels, December 2016), p. 44.
134 Based on the findings of an international conference on 
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Fig. 24 Annual drug users obtaining drugs 
over the darknet in the past 12 months, 
2014-2017
Note: Based on annual information from more than 60,000 past-
year drug users. In 2014, the question was asked specifically in 
relation to the Silk Road, the then dominant darknet market, as 
the survey was conducted just after the Silk Road's closure; from 
2015, the question was asked in relation to all darknet markets.
Sources: Global Drug Survey 2017 findings (www.globaldrug-
survey.com); and Global Drug Survey 2017, detailed findings 
on drug cryptomarkets. Available from Dr. Monica Barratt, 
National Drug and Alcohol Research Centre, Australia.
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Fig. 25  Number of transactions by substance, and market share of transactions by substance on 
the darknet, September 2013-January 2016
a Amphetamines and cocaine
Source: Kruithof and others, Internet-facilitated Drugs Trade.
cent), followed by Europe (more than 32 per cent)
and Oceania (more than 7 per cent). Most revenue 
was made in North America and Europe and most 
of the sales and purchases took place in the same 
regions. The largest interregional traffic was from 
Asia to North America. In terms of e-mail addresses 
linked to drug listings, another study finding was 
the dominance of North America (43 per cent) and 
Europe (more than 32 per cent), followed by Asia 
(more than 13 per cent, mostly China, followed by 
India and Afghanistan) and Oceania (more than 9 
per cent). Vendors in countries in Asia seemed to 
be more involved in the wholesale business, while 
retail sales were dominated by vendors in North 
America and Europe. 
The study suggested that transactions for all drug 
types had increased. Overall, the value of transactions 
in the eight markets that dominated the darknet in 
January 2016 was 2.6 times greater than that of 
transactions on the Silk Road market in September 
2013, which dominated the darknet at that time. 
That is equivalent to an average annual growth of 
some 50 per cent during that period. Above-average 
growth rates of transactions were identified for 
stimulants (cocaine and amphetamines) and 
cannabis, while growth in “psychedelics” turned out 
“Ecstasy”, cannabis, LSD and NPS138 were the drugs 
that Global Drug Survey respondents most com-
monly obtained over the darknet in 2017.139
Another study140 used “web scraping/crawling” tech-
niques141 to look at eight major darknet markets 
that were in existence as of January 2016 (AlphaBay, 
Cryptomarket, Dark Net Heroes League, Dream-
market, French Dark Net, Hansa, Nucleus and 
Python) and which accounted for 106,000 listings, 
representing around three quarters of all listings on 
the darknet. Based on the activities of identified 
vendors, the study found that 71 per cent of vendors 
in those eight darknet markets sold drugs (includ-
ing 62 per cent who sold only drugs and drug-related 
products and 9 per cent who sold drugs and non-
drug-related products) and only 29 per cent operated 
exclusively in other activities. The largest share of 
those vendors was located in North America (38 per 
138 The definition of NPS used in the Global Drug Survey is 
not comparable to the definition used by the UNODC.
139 Global Drug Survey 2017, Detailed findings on drug  
cryptomarkets. Available from Dr. Monica Barratt, National 
Drug and Alcohol Research Centre, Australia. 
140 Kruithof and others, Internet-facilitated Drugs Trade: An 
Analysis of the Size, Scope and the Role of the Netherlands.
141 For further details, see the online methodology section of 
the World Drug Report 2017.
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2 GLOBAL OVERVIEW OF DRUG DEMAND AND SUPPLY D. Extent of drug supply
pean Union: 24.3 billion euros in 2013),148 the 
overall revenue calculated by the study (from $14.2 
million to $25 million per month, or equivalent to 
between $170 million and $300 million per annum) 
is, however, rather small. Nevertheless, caution needs 
to be applied as the methodology used in the study 
is likely to have underestimated the amount pur-
chased per transaction, and thus overall revenue. 
In the Netherlands, a further study,149 based on 
samples submitted by users for anonymous testing 
purposes (32,663 drug samples from January 2013 
to January 2016), revealed that the total proportion 
of online purchases tripled, from 1.4 per cent in 
2013 to 4.1 per cent in 2015. Overall, 15 per cent 
of the drug users who had purchased drugs online 
used the darknet for those purchases over the period 
2013-2015 and 26 per cent used Google-indexed 
webshops; no additional information was obtained 
for the remaining 59 per cent. This suggests that 
the proportion of drugs purchased in the Nether-
lands over the darknet ranged from 0.6 per cent to 
1.5 per cent in 2015.150 
That study also suggested that more than one third 
of NPS samples were bought online (very few over 
the darknet), while online purchases of each con-
trolled substance did not exceed 6 per cent (“ecstasy”: 
148 European Drug Report 2016: Trends and Developments.
149 Daan van der Gouwe and others, “Purity, adulteration and 
price of drugs bought on-line versus off-line in the Nether-
lands”, Addiction vol. 112, No. 4 (April 2017), pp. 640-648.
150 For further details on the calculation, see the online meth-
odology section of the World Drug Report 2017.
to be below average. The growth rates for prescription 
drugs, “ecstasy” and opioids was close to the overall 
average. 
The study also calculated “minimum” revenue by 
multiplying the number of transactions by the prices 
listed (assuming the purchase of one unit per trans-
action), thus arriving at monthly minimum revenues 
of $14.2 million. This was twice the minimum rev-
enue (based on the same methodology) calculated 
for the Silk Road in September 2013. 
Sales of cannabis, stimulants (cocaine and ampheta-
mine) and “ecstasy” accounted for 70 per cent of 
total drug-related revenues in the eight darknet mar-
kets investigated.142 When compared with the 
overall distribution of drugs in the United States143 
and European Union144 markets, methamphetamine 
and heroin appear to be underrepresented on the 
darknet, while “ecstasy” and “psychedelics” (hallu-
cinogens) are overrepresented in sales over the 
darknet.145, 146 
The largest share of transactions in the eight markets 
considered in the study (64 per cent) concerned 
transactions of less than $100, typical of what one 
would expect of retail sales to the end consumer. 
However, such sales only accounted for 18 per cent 
of total revenue, with most revenue (57 per cent) 
being generated by transactions of $100-$1,000. 
Transactions exceeding $1,000 accounted for 25 per 
cent of total revenue, suggesting that large wholesale 
business activities to date are not really taking place 
to a significant extent over the darknet and that drug 
cartels and other large organizations are apparently 
not yet that involved in the buying and selling of 
drugs over the darknet. 
Equivalent to just 0.1-0.2 per cent of combined 
United States and European Union drug market 
sales (United States: $109 billion in 2010;147 Euro-
142 Kruithof and others, Internet-facilitated Drugs Trade: An 
Analysis of the Size, Scope and the Role of the Netherlands.
143 Beau Kilmer and others, What America’s Users Spend on 
Illegal Drugs: 2000-2010 (Santa Monica, California, Rand 
Corporation, 2014). 
144 European Drug Report 2016: Trends and Developments. 
145 Global Drug Survey 2016, “Results of the world’s biggest 
drug survey”
146 Kruithof and others, Internet-facilitated Drugs Trade: An 
Analysis of the Size, Scope and the Role of the Netherlands.
147 Kilmer and others, What America’s Users Spend on Illegal 
Drugs. 
DARKNET
drug
transactions
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DARKNET
Drug trafficking over the darknet
still small but fast growing
<1%
+50%
increase
201
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3
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Source: Kristy Kruithof and others, Internet-facilitated Drugs Trade:  
An Analysis of the Size, Scope and the Role of the Netherlands.
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1 per cent; cocaine: 1 per cent; LSD: 5 per cent). 
Although purchases of controlled substances over 
the darknet were significant (LSD: 53 per cent; 
amphetamine: 48 per cent; cocaine: 46 per cent; 
“ecstasy”: 35 per cent), no online purchases of heroin 
were recorded. In contrast to general perceptions, 
the purity of drugs bought online was, on average, 
no better than of drugs purchased elsewhere in the 
Netherlands. Prices of drugs purchased online were 
on average, however, 10-23 per cent higher than of 
drugs purchased elsewhere.
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ANNEX Opium/Heroin 2
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GLOSSARY
amphetamine-type stimulants — a group of sub-
stances composed of synthetic stimulants that were 
placed under international control in the Conven-
tion on Psychotropic Substances of 1971 and are 
from the group of substances called amphetamines, 
which includes amphetamine, methamphetamine, 
methcathinone and the “ecstasy”-group substances 
(3,4-methylenedioxymethamphetamine (MDMA) 
and its analogues).
amphetamines — a group of amphetamine-type 
stimulants that includes amphetamine and 
methamphetamine.
annual prevalence — the total number of people of 
a given age range who have used a given drug at 
least once in the past year, divided by the number 
of people of the given age range, and expressed as a 
percentage.
coca paste (or coca base) — an extract of the leaves 
of the coca bush. Purification of coca paste yields 
cocaine (base and hydrochloride).
“crack” cocaine — cocaine base obtained from 
cocaine hydrochloride through conversion processes 
to make it suitable for smoking.
cocaine salt — cocaine hydrochloride.
new psychoactive substances — substances of abuse, 
either in a pure form or a preparation, that are not 
controlled under the Single Convention on Narcotic 
Drugs of 1961 or the 1971 Convention, but that 
may pose a public health threat. In this context, the 
term “new” does not necessarily refer to new inven-
tions but to substances that have recently become 
available.
opiates — a subset of opioids comprising the various 
products derived from the opium poppy plant, 
including opium, morphine and heroin.
opioids — a generic term applied to alkaloids from 
opium poppy (opiates), their synthetic analogues 
(mainly prescription or pharmaceutical opioids) and 
compounds synthesized in the body.
problem drug users — people who engage in the 
high-risk consumption of drugs; for example, people 
who inject drugs, people who use drugs on a daily 
basis and/or people diagnosed with drug use disor-
ders (harmful use or drug dependence), based on 
clinical criteria as contained in the Diagnostic and 
Statistical Manual of Mental Disorders (fifth edi-
tion) of the American Psychiatric Association, or 
the International Classification of Diseases (tenth 
revision) of the World Health Organization. 
people who suffer from drug use disorders/people with 
drug use disorders — a subset of people who use 
drugs. People with drug use disorders need treat-
ment, health and social care and rehabilitation. 
Dependence is a drug use disorder. 
prevention of drug use and treatment of drug use dis-
orders — the aim of “prevention of drug use” is to 
prevent or delay the initiation of drug use, as well 
as the transition to drug use disorders. Once there 
is a drug use disorder, treatment, care and rehabili-
tation are needed.
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REGIONAL GROUPINGS  
• Central Asia and Transcaucasia: Armenia, 
Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, 
Tajikistan, Turkmenistan and Uzbekistan
• East and South-East Asia: Brunei Darussalam, 
Cambodia, China, Democratic People’s 
Republic of Korea, Indonesia, Japan, Lao 
People’s Democratic Republic, Malaysia, 
Mongolia, Myanmar, Philippines, Republic of 
Korea, Singapore, Thailand, Timor-Leste and 
Viet Nam 
• South-West Asia: Afghanistan, Iran (Islamic 
Republic of ) and Pakistan 
• Near and Middle East: Bahrain, Iraq, Israel, 
Jordan, Kuwait, Lebanon, Oman, Qatar, Saudi 
Arabia, State of Palestine, Syrian Arab Republic, 
United Arab Emirates and Yemen
• South Asia: Bangladesh, Bhutan, India, 
Maldives, Nepal and Sri Lanka 
• Eastern Europe: Belarus, Republic of Moldova, 
Russian Federation and Ukraine
• South-Eastern Europe: Albania, Bosnia and 
Herzegovina, Bulgaria, Croatia, Montenegro, 
Romania, Serbia, the former Yugoslav Republic 
of Macedonia and Turkey
• Western and Central Europe: Andorra, Austria, 
Belgium, Cyprus, Czechia, Denmark, Estonia, 
Finland, France, Germany, Greece, Hungary, 
Iceland, Ireland, Italy, Latvia, Liechtenstein, 
Lithuania, Luxembourg, Malta, Monaco, 
Netherlands, Norway, Poland, Portugal, San 
Marino, Slovakia, Slovenia, Spain, Sweden, 
Switzerland and United Kingdom of Great 
Britain and Northern Ireland
• Oceania: Australia, Fiji, Kiribati, Marshall 
Islands, Micronesia (Federated States of ), 
Nauru, New Zealand, Palau, Papua New 
Guinea, Samoa, Solomon Islands, Tonga, 
Tuvalu, Vanuatu and small island territories
The World Drug Report uses a number of regional 
and subregional designations. These are not official 
designations, and are defined as follows:
• East Africa: Burundi, Comoros, Djibouti, 
Eritrea, Ethiopia, Kenya, Madagascar, 
Mauritius, Rwanda, Seychelles, Somalia, 
Uganda and United Republic of Tanzania 
• North Africa: Algeria, Egypt, Libya, Morocco, 
South Sudan, Sudan and Tunisia
• Southern Africa: Angola, Botswana, Lesotho, 
Malawi, Mozambique, Namibia, South Africa, 
Swaziland, Zambia and Zimbabwe
• West and Central Africa: Benin, Burkina Faso, 
Cameroon, Cabo Verde, Central African 
Republic, Chad, Congo, Côte d’Ivoire, 
Democratic Republic of the Congo, Equatorial 
Guinea, Gabon, Gambia, Ghana, Guinea, 
Guinea-Bissau, Liberia, Mali, Mauritania, 
Niger, Nigeria, Sao Tome and Principe, Senegal, 
Sierra Leone and Togo 
• Caribbean: Antigua and Barbuda, Bahamas, 
Barbados, Bermuda, Cuba, Dominica, 
Dominican Republic, Grenada, Haiti, Jamaica, 
Saint Kitts and Nevis, Saint Lucia, Saint 
Vincent and the Grenadines and Trinidad and 
Tobago
• Central America: Belize, Costa Rica,  
El Salvador, Guatemala, Honduras, Nicaragua 
and Panama
• North America: Canada, Mexico and United 
States of America 
• South America: Argentina, Bolivia 
(Plurinational State of ), Brazil, Chile, 
Colombia, Ecuador, Guyana, Paraguay, Peru, 
Suriname, Uruguay and Venezuela (Bolivarian 
Republic of )
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To celebrate 20 years since its inception, the World Drug 
Report 2017 is presented in a new five-booklet format 
designed to improve reader friendliness while maintaining the 
wealth of information contained within. 
Booklet 1 summarizes the content of the four subsequent 
substantive booklets and presents policy implications drawn 
from their findings. Booklet 2 deals with the supply, use and 
health consequences of drugs. Booklet 3 focuses on the 
cultivation, production and consumption of the three 
plant-based drugs (cocaine, opiates and cannabis) and on the 
impact of new cannabis policies. Booklet 4 provides an 
extended analysis of the global synthetic drugs market and 
contains the bulk of the analysis for the triennial global 
synthetic drugs assessment. Finally, Booklet 5 contains a 
discussion on the nexus between the drug problem, organized 
crime, illicit financial flows, corruption and terrorism.
 
Enhanced by this new format, the World Drug Report 2017 is, 
as ever, aimed at improving the understanding of the world 
drug problem and contributing towards fostering greater 
international cooperation for countering its impact on health 
and security.
The statistical annex is published on the UNODC website: 
www.unodc.org/wdr/2017
